{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:44:08Z","timestamp":1795009448598,"version":"4.9.1"},"reference-count":473,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent years, the incidence of acute respiratory distress syndrome (ARDS) has been gradually increasing. Despite advances in supportive care, ARDS remains a significant cause of morbidity and mortality in critically ill patients. ARDS is characterized by acute hypoxaemic respiratory failure with diffuse pulmonary inflammation and bilateral edema due to excessive alveolocapillary permeability in patients with non-cardiogenic pulmonary diseases. Over the past seven decades, our understanding of the pathology and clinical characteristics of ARDS has evolved significantly, yet it remains an area of active research and discovery. ARDS is highly heterogeneous, including diverse pathological causes, clinical presentations, and treatment responses, presenting a significant challenge for clinicians and researchers. In this review, we comprehensively discuss the latest advancements in ARDS research, focusing on its heterogeneity, pathophysiological mechanisms, and emerging therapeutic approaches, such as cellular therapy, immunotherapy, and targeted therapy. Moreover, we also examine the pathological characteristics of COVID-19-related ARDS and discuss the corresponding therapeutic approaches. In the face of challenges posed by ARDS heterogeneity, recent advancements offer hope for improved patient outcomes. Further research is essential to translate these findings into effective clinical interventions and personalized treatment approaches for ARDS, ultimately leading to better outcomes for patients suffering from ARDS.<\/jats:p>","DOI":"10.1038\/s41392-025-02127-9","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:01:46Z","timestamp":1741287706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies"],"prefix":"10.1038","volume":"10","author":[{"given":"Wen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-2760","authenticated-orcid":false,"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"2127_CR1","first-page":"7","volume":"68","author":"MT Jenkins","year":"1950","unstructured":"Jenkins, M. T., Jones, R. F., Wilson, B. & Moyer, C. A. Congestive atelectasis; a complication of the intravenous infusion of fluids. Trans. Meet. Am. Surg. Assoc. Am. Surg. Assoc. 68, 7\u201327 (1950).","journal-title":"Trans. Meet. Am. Surg. Assoc. Am. Surg. Assoc."},{"key":"2127_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(67)90168-7","volume":"2","author":"DG Ashbaugh","year":"1967","unstructured":"Ashbaugh, D. G., Bigelow, D. B., Petty, T. L. & Levine, B. E. Acute respiratory distress in adults. Lancet 2, 319\u2013323 (1967).","journal-title":"Lancet"},{"key":"2127_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1378\/chest.60.3.233","volume":"60","author":"TL Petty","year":"1971","unstructured":"Petty, T. L. & Ashbaugh, D. G. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest 60, 233\u2013239 (1971).","journal-title":"Chest"},{"key":"2127_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1164\/ajrccm\/138.3.720","volume":"138","author":"JF Murray","year":"1988","unstructured":"Murray, J. F., Matthay, M. A., Luce, J. M. & Flick, M. R. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138, 720\u2013723 (1988).","journal-title":"Am. Rev. Respir. Dis."},{"key":"2127_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1542\/peds.50.4.526","volume":"50","author":"M Baden","year":"1972","unstructured":"Baden, M. et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50, 526\u2013534 (1972).","journal-title":"Pediatrics"},{"key":"2127_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1542\/peds.50.4.515","volume":"50","author":"GC Liggins","year":"1972","unstructured":"Liggins, G. C. & Howie, R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50, 515\u2013525 (1972).","journal-title":"Pediatrics"},{"key":"2127_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF01704707","volume":"20","author":"GR Bernard","year":"1994","unstructured":"Bernard, G. R. et al. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 20, 225\u2013232 (1994).","journal-title":"Intensive Care Med"},{"key":"2127_CR8","first-page":"2526","volume":"307","author":"ADT Force","year":"2012","unstructured":"Force, A. D. T. et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307, 2526\u20132533 (2012).","journal-title":"JAMA"},{"key":"2127_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1164\/rccm.201503-0584OC","volume":"193","author":"ED Riviello","year":"2016","unstructured":"Riviello, E. D. et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali Modification of the Berlin definition. Am. J. Respir. Crit. Care Med 193, 52\u201359 (2016).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR10","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1007\/s00134-020-06296-9","volume":"46","author":"MA Matthay","year":"2020","unstructured":"Matthay, M. A. et al. Phenotypes and personalized medicine in the acute respiratory distress syndrome. Intensive Care Med 46, 2136\u20132152 (2020).","journal-title":"Intensive Care Med"},{"key":"2127_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-023-00658-3","volume":"11","author":"S Fujishima","year":"2023","unstructured":"Fujishima, S. Guideline-based management of acute respiratory failure and acute respiratory distress syndrome. J. Intensive Care 11, 10 (2023).","journal-title":"J. Intensive Care"},{"key":"2127_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S2213-2600(22)00058-3","volume":"10","author":"KD Wick","year":"2022","unstructured":"Wick, K. D., Matthay, M. A. & Ware, L. B. Pulse oximetry for the diagnosis and management of acute respiratory distress syndrome. Lancet Respir. Med 10, 1086\u20131098 (2022).","journal-title":"Lancet Respir. Med"},{"key":"2127_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1606-4","volume":"21","author":"JM Peng","year":"2017","unstructured":"Peng, J. M. et al. Does training improve diagnostic accuracy and inter-rater agreement in applying the Berlin radiographic definition of acute respiratory distress syndrome? A multicenter prospective study. Crit. Care 21, 12 (2017).","journal-title":"Crit. Care"},{"key":"2127_CR14","doi-asserted-by":"publisher","first-page":"672823","DOI":"10.3389\/fphys.2021.672823","volume":"12","author":"C Zimatore","year":"2021","unstructured":"Zimatore, C. et al. Accuracy of the Radiographic assessment of lung Edema score for the diagnosis of ARDS. Front Physiol. 12, 672823 (2021).","journal-title":"Front Physiol."},{"key":"2127_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41746-023-00797-9","volume":"6","author":"N Farzaneh","year":"2023","unstructured":"Farzaneh, N. et al. Collaborative strategies for deploying artificial intelligence to complement physician diagnoses of acute respiratory distress syndrome. NPJ Digit Med. 6, 62 (2023).","journal-title":"NPJ Digit Med."},{"key":"2127_CR16","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/bioengineering10080946","volume":"10","author":"M Arora","year":"2023","unstructured":"Arora, M. et al. Uncertainty-aware convolutional neural network for identifying bilateral opacities on Chest X-rays: A tool to aid diagnosis of acute respiratory distress syndrome. Bioengineering 10, 946 (2023).","journal-title":"Bioengineering"},{"key":"2127_CR17","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/CCM.0000000000006118","volume":"52","author":"C Plantinga","year":"2024","unstructured":"Plantinga, C. et al. Use of lung ultrasound in the new definitions of acute respiratory distress syndrome increases the occurrence rate of acute respiratory distress syndrome. Crit. Care Med 52, e100\u2013e104 (2024).","journal-title":"Crit. Care Med"},{"key":"2127_CR18","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.accpm.2020.100795","volume":"40","author":"L Papazian","year":"2021","unstructured":"Papazian, L. et al. National incidence rate and related mortality for acute respiratory distress syndrome in France. Anaesth. Crit. Care Pain. Med 40, 100795 (2021).","journal-title":"Anaesth. Crit. Care Pain. Med"},{"key":"2127_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.201003-0436OC","volume":"183","author":"G Li","year":"2011","unstructured":"Li, G. et al. Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am. J. Respir. Crit. Care Med. 183, 59\u201366 (2011).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s00134-009-1519-z","volume":"35","author":"R Linko","year":"2009","unstructured":"Linko, R. et al. Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive Care Med 35, 1352\u20131361 (2009).","journal-title":"Intensive Care Med"},{"key":"2127_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.2017.21907","volume":"319","author":"E Fan","year":"2018","unstructured":"Fan, E., Brodie, D. & Slutsky, A. S. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA 319, 698\u2013710 (2018).","journal-title":"JAMA"},{"key":"2127_CR22","doi-asserted-by":"publisher","first-page":"1900609","DOI":"10.1183\/13993003.00609-2019","volume":"54","author":"BA McNicholas","year":"2019","unstructured":"McNicholas, B. A. et al. Demographics, management and outcome of females and males with acute respiratory distress syndrome in the LUNG SAFE prospective cohort study. Eur. Respir. J. 54, 1900609 (2019).","journal-title":"Eur. Respir. J."},{"key":"2127_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2016.0291","volume":"315","author":"G Bellani","year":"2016","unstructured":"Bellani, G. et al. EpidemiologY, Patterns Of Care, And Mortality For Patients With Acute Respiratory Distress Syndrome In Intensive Care Units In 50 Countries. JAMA 315, 788\u2013800 (2016).","journal-title":"JAMA"},{"key":"2127_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-022-01124-6","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Mesenchymal stromal cells alleviate acute respiratory distress syndrome through the cholinergic anti-inflammatory pathway. Signal Transduct. Target Ther. 7, 307 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2127_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MCC.0000000000000266","volume":"22","author":"J Villar","year":"2016","unstructured":"Villar, J., Blanco, J. & Kacmarek, R. M. Current incidence and outcome of the acute respiratory distress syndrome. Curr. Opin. Crit. Care 22, 1\u20136 (2016).","journal-title":"Curr. Opin. Crit. Care"},{"key":"2127_CR26","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.21037\/jtd.2018.08.137","volume":"10","author":"L Liu","year":"2018","unstructured":"Liu, L. et al. Practice of diagnosis and management of acute respiratory distress syndrome in mainland China: a cross-sectional study. J. Thorac. Dis. 10, 5394\u20135404 (2018).","journal-title":"J. Thorac. Dis."},{"key":"2127_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03112-0","volume":"24","author":"X Huang","year":"2020","unstructured":"Huang, X. et al. Incidence and outcomes of acute respiratory distress syndrome in intensive care units of mainland China: a multicentre prospective longitudinal study. Crit. Care 24, 515 (2020).","journal-title":"Crit. Care"},{"key":"2127_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 180, 934\u2013943 (2020).","journal-title":"JAMA Intern Med"},{"key":"2127_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475\u2013481 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR30","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1161\/STROKEAHA.120.030365","volume":"51","author":"C Qin","year":"2020","unstructured":"Qin, C. et al. Clinical characteristics and outcomes of COVID-19 patients with a history of Stroke in Wuhan, China. Stroke 51, 2219\u20132223 (2020).","journal-title":"Stroke"},{"key":"2127_CR31","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/S2214-109X(21)00485-X","volume":"10","author":"L Pisani","year":"2022","unstructured":"Pisani, L. et al. Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies. Lancet Glob. Health 10, e227\u2013e235 (2022).","journal-title":"Lancet Glob. Health"},{"key":"2127_CR32","doi-asserted-by":"publisher","first-page":"n436","DOI":"10.1136\/bmj.n436","volume":"372","author":"AH Attaway","year":"2021","unstructured":"Attaway, A. H. et al. Severe COVID-19 pneumonia: pathogenesis and clinical management. BMJ 372, n436 (2021).","journal-title":"BMJ"},{"key":"2127_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jinf.2021.08.018","volume":"83","author":"J Aranda","year":"2021","unstructured":"Aranda, J. et al. Long-term impact of COVID-19 associated acute respiratory distress syndrome. J. Infect. 83, 581\u2013588 (2021).","journal-title":"J. Infect."},{"key":"2127_CR34","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1097\/CCM.0000000000001089","volume":"43","author":"CS Calfee","year":"2015","unstructured":"Calfee, C. S. et al. Cigarette smoke exposure and the acute respiratory distress syndrome. Crit. Care Med 43, 1790\u20131797 (2015).","journal-title":"Crit. Care Med"},{"key":"2127_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1164\/rccm.202105-1098OC","volume":"205","author":"F Moazed","year":"2022","unstructured":"Moazed, F. et al. Cigarette smoke exposure and acute respiratory distress syndrome in sepsis: epidemiology, clinical features, and biologic markers. Am. J. Respir. Crit. Care Med 205, 927\u2013935 (2022).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.chest.2017.11.041","volume":"154","author":"E Simou","year":"2018","unstructured":"Simou, E., Leonardi-Bee, J. & Britton, J. The effect of alcohol consumption on the risk of ARDS: A systematic review and meta-analysis. Chest 154, 58\u201368 (2018).","journal-title":"Chest"},{"key":"2127_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1513\/AnnalsATS.202108-963CME","volume":"19","author":"P Toy","year":"2022","unstructured":"Toy, P. et al. Transfusion-related acute lung injury: 36 years of progress (1985\u20132021). Ann. Am. Thorac. Soc. 19, 705\u2013712 (2022).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2127_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.15585\/mmwr.mm6903e2","volume":"69","author":"VP Krishnasamy","year":"2020","unstructured":"Krishnasamy, V. P. et al. Update: Characteristics of a nationwide outbreak of E-cigarette, or Vaping, product use-associated lung injury - United States, August 2019-January 2020. MMWR Morb. Mortal. Wkly Rep. 69, 90\u201394 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2127_CR39","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1056\/NEJMoa1911614","volume":"382","author":"JE Layden","year":"2020","unstructured":"Layden, J. E. et al. Pulmonary illness related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N. Engl. J. Med. 382, 903\u2013916 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR40","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1165\/rcmb.2020-0209OC","volume":"63","author":"S Matsumoto","year":"2020","unstructured":"Matsumoto, S. et al. Dose-dependent pulmonary toxicity of aerosolized Vitamin E Acetate. Am. J. Respir. Cell Mol. Biol. 63, 748\u2013757 (2020).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2127_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1164\/rccm.201803-0435OC","volume":"199","author":"JP Reilly","year":"2019","unstructured":"Reilly, J. P. et al. Low to moderate air pollutant exposure and acute respiratory distress syndrome after severe trauma. Am. J. Respir. Crit. Care Med. 199, 62\u201370 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR42","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1164\/rccm.201507-1418OC","volume":"193","author":"LB Ware","year":"2016","unstructured":"Ware, L. B. et al. Long-term Ozone exposure increases the risk of developing the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 193, 1143\u20131150 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(22)01485-4","volume":"400","author":"LDJ Bos","year":"2022","unstructured":"Bos, L. D. J. & Ware, L. B. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet 400, 1145\u20131156 (2022).","journal-title":"Lancet"},{"key":"2127_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5918954","volume":"2022","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. Magnesium Hydride Ameliorates Endotoxin-induced acute respiratory distress syndrome by inhibiting inflammation, oxidative stress, and cell apoptosis. Oxid. Med Cell Longev. 2022, 5918954 (2022).","journal-title":"Oxid. Med Cell Longev."},{"key":"2127_CR45","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/ijms21093382","volume":"21","author":"P Kosutova","year":"2020","unstructured":"Kosutova, P. et al. Effects of PDE3 Inhibitor Olprinone on the Respiratory Parameters, Inflammation, and Apoptosis in an Experimental Model of Acute Respiratory Distress Syndrome. Int. J. Mol. Sci. 21, 3382 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2127_CR46","doi-asserted-by":"publisher","first-page":"2100377","DOI":"10.1183\/13993003.00377-2021","volume":"58","author":"A Birnhuber","year":"2021","unstructured":"Birnhuber, A. et al. Between inflammation and thrombosis: endothelial cells in COVID-19. Eur. Respir. J. 58, 2100377 (2021).","journal-title":"Eur. Respir. J."},{"key":"2127_CR47","doi-asserted-by":"publisher","first-page":"101638","DOI":"10.1016\/j.redox.2020.101638","volume":"36","author":"J Jiang","year":"2020","unstructured":"Jiang, J. et al. Targeting NOX4 alleviates sepsis-induced acute lung injury via attenuation of redox-sensitive activation of CaMKII\/ERK1\/2\/MLCK and endothelial cell barrier dysfunction. Redox Biol. 36, 101638 (2020).","journal-title":"Redox Biol."},{"key":"2127_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1164\/rccm.202106-1514OC","volume":"205","author":"DE Leisman","year":"2022","unstructured":"Leisman, D. E. et al. Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. Am. J. Respir. Crit. Care Med. 205, 507\u2013519 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-00488-7","volume":"8","author":"MN Benatti","year":"2020","unstructured":"Benatti, M. N., Fabro, A. T. & Miranda, C. H. Endothelial glycocalyx shedding in the acute respiratory distress syndrome after flu syndrome. J. Intensive Care 8, 72 (2020).","journal-title":"J. Intensive Care"},{"key":"2127_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.aaz8455","volume":"368","author":"O Gilan","year":"2020","unstructured":"Gilan, O. et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science 368, 387\u2013394 (2020).","journal-title":"Science"},{"key":"2127_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.psychres.2015.08.029","volume":"230","author":"Y Liu","year":"2015","unstructured":"Liu, Y., Zhang, D., Cheng, Y. & Li, Z. Elevated serum immunoinflammation-related protein complexes are associated with psychosis. Psychiatry Res. 230, 96\u2013101 (2015).","journal-title":"Psychiatry Res."},{"key":"2127_CR52","doi-asserted-by":"publisher","first-page":"2002049","DOI":"10.1183\/13993003.02049-2020","volume":"56","author":"MA Torres Acosta","year":"2020","unstructured":"Torres Acosta, M. A. & Singer, B. D. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur. Respir. J. 56, 2002049 (2020).","journal-title":"Eur. Respir. J."},{"key":"2127_CR53","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1007\/s00134-020-06292-z","volume":"46","author":"CE Luyt","year":"2020","unstructured":"Luyt, C. E. et al. Pulmonary infections complicating ARDS. Intensive Care Med 46, 2168\u20132183 (2020).","journal-title":"Intensive Care Med"},{"key":"2127_CR54","doi-asserted-by":"publisher","first-page":"687506","DOI":"10.3389\/fimmu.2021.687506","volume":"12","author":"D Li","year":"2021","unstructured":"Li, D., Pan, L., Zhang, X. & Jiang, Z. Lower oligomeric form of surfactant protein D in murine acute lung injury induces M1 subtype macrophages through Calreticulin\/p38 MAPK signaling pathway. Front Immunol. 12, 687506 (2021).","journal-title":"Front Immunol."},{"key":"2127_CR55","doi-asserted-by":"publisher","first-page":"eabf8654","DOI":"10.1126\/scitranslmed.abf8654","volume":"13","author":"W Hoepel","year":"2021","unstructured":"Hoepel, W. et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci. Transl. Med. 13, eabf8654 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2127_CR56","doi-asserted-by":"publisher","first-page":"865579","DOI":"10.3389\/fimmu.2022.865579","volume":"13","author":"Q Shen","year":"2022","unstructured":"Shen, Q. et al. Soluble SIRP-Alpha Promotes Murine Acute Lung Injury Through Suppressing Macrophage Phagocytosis. Front Immunol. 13, 865579 (2022).","journal-title":"Front Immunol."},{"key":"2127_CR57","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41580-020-0232-1","volume":"21","author":"E Boada-Romero","year":"2020","unstructured":"Boada-Romero, E., Martinez, J., Heckmann, B. L. & Green, D. R. The clearance of dead cells by efferocytosis. Nat. Rev. Mol. Cell Biol. 21, 398\u2013414 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2127_CR58","doi-asserted-by":"publisher","first-page":"2100880","DOI":"10.1183\/13993003.00880-2021","volume":"59","author":"M Yamashita","year":"2022","unstructured":"Yamashita, M. et al. VEGF-C\/VEGFR-3 signalling in macrophages ameliorates acute lung injury. Eur. Respir. J. 59, 2100880 (2022).","journal-title":"Eur. Respir. J."},{"key":"2127_CR59","doi-asserted-by":"publisher","first-page":"627548","DOI":"10.3389\/fimmu.2021.627548","volume":"12","author":"MA Zingaropoli","year":"2021","unstructured":"Zingaropoli, M. A. et al. Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. Front Immunol. 12, 627548 (2021).","journal-title":"Front Immunol."},{"key":"2127_CR60","doi-asserted-by":"publisher","first-page":"1702590","DOI":"10.1183\/13993003.02590-2017","volume":"52","author":"M Gregoire","year":"2018","unstructured":"Gregoire, M. et al. Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS. Eur. Respir. J. 52, 1702590 (2018).","journal-title":"Eur. Respir. J."},{"key":"2127_CR61","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/ATVBAHA.120.315267","volume":"41","author":"H Ng","year":"2021","unstructured":"Ng, H. et al. Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. Arterioscler Thromb. Vasc. Biol. 41, 988\u2013994 (2021).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"2127_CR62","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2967\/jnumed.122.264306","volume":"64","author":"E Puuvuori","year":"2023","unstructured":"Puuvuori, E. et al. PET Imaging of Neutrophil Elastase with (11)C-GW457427 in Acute Respiratory Distress Syndrome in Pigs. J. Nucl. Med 64, 423\u2013429 (2023).","journal-title":"J. Nucl. Med"},{"key":"2127_CR63","doi-asserted-by":"publisher","first-page":"1902354","DOI":"10.1183\/13993003.02354-2019","volume":"56","author":"C Zhu","year":"2020","unstructured":"Zhu, C. et al. Homeostatic and early-recruited CD101(-) eosinophils suppress endotoxin-induced acute lung injury. Eur. Respir. J. 56, 1902354 (2020).","journal-title":"Eur. Respir. J."},{"key":"2127_CR64","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-020-03148-w","volume":"590","author":"RA Grant","year":"2021","unstructured":"Grant, R. A. et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature 590, 635\u2013641 (2021).","journal-title":"Nature"},{"key":"2127_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03440-1","volume":"25","author":"P Cuvelier","year":"2021","unstructured":"Cuvelier, P. et al. Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome. Crit. Care 25, 4 (2021).","journal-title":"Crit. Care"},{"key":"2127_CR66","doi-asserted-by":"publisher","first-page":"e20200872","DOI":"10.1084\/jem.20200872","volume":"217","author":"Y Jouan","year":"2020","unstructured":"Jouan, Y. et al. Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients. J. Exp. Med. 217, e20200872 (2020).","journal-title":"J. Exp. Med."},{"key":"2127_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27716-4","volume":"13","author":"A Unterman","year":"2022","unstructured":"Unterman, A. et al. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat. Commun. 13, 440 (2022).","journal-title":"Nat. Commun."},{"key":"2127_CR68","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","volume":"588","author":"J Carvelli","year":"2020","unstructured":"Carvelli, J. et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 588, 146\u2013150 (2020).","journal-title":"Nature"},{"key":"2127_CR69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2021.12.040","volume":"185","author":"P Georg","year":"2022","unstructured":"Georg, P. et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell 185, 493\u2013512 e425 (2022).","journal-title":"Cell"},{"key":"2127_CR70","doi-asserted-by":"publisher","first-page":"768435","DOI":"10.3389\/fimmu.2021.768435","volume":"12","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Extracellular CIRP-impaired Rab26 Restrains EPOR-mediated macrophage polarization in acute lung injury. Front. Immunol. 12, 768435 (2021).","journal-title":"Front. Immunol."},{"key":"2127_CR71","doi-asserted-by":"publisher","first-page":"2002536","DOI":"10.1183\/13993003.02536-2020","volume":"57","author":"H Quijada","year":"2021","unstructured":"Quijada, H. et al. Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody. Eur. Respir. J. 57, 2002536 (2021).","journal-title":"Eur. Respir. J."},{"key":"2127_CR72","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169\u20131179 (2020).","journal-title":"Blood"},{"key":"2127_CR73","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1172\/JCI141374","volume":"130","author":"P Skendros","year":"2020","unstructured":"Skendros, P. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 130, 6151\u20136157 (2020).","journal-title":"J. Clin. Invest."},{"key":"2127_CR74","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00134-021-06419-w","volume":"47","author":"JS O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell, J. S., Peyvandi, F. & Martin-Loeches, I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Med. 47, 899\u2013902 (2021).","journal-title":"Intensive Care Med"},{"key":"2127_CR75","doi-asserted-by":"publisher","first-page":"e144075","DOI":"10.1172\/JCI144075","volume":"131","author":"AN Rizzo","year":"2021","unstructured":"Rizzo, A. N. & Schmidt, E. P. ABO blood type: a window into the genetics of acute respiratory distress syndrome susceptibility. J. Clin. Invest. 131, e144075 (2021).","journal-title":"J. Clin. Invest."},{"key":"2127_CR76","doi-asserted-by":"publisher","first-page":"e139700","DOI":"10.1172\/JCI139700","volume":"131","author":"JP Reilly","year":"2021","unstructured":"Reilly, J. P. et al. The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness. J. Clin. Invest. 131, e139700 (2021).","journal-title":"J. Clin. Invest."},{"key":"2127_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12929-022-00832-z","volume":"29","author":"PS Sung","year":"2022","unstructured":"Sung, P. S. et al. CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation. J. Biomed. Sci. 29, 52 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2127_CR78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41590-019-0571-2","volume":"21","author":"JM Adrover","year":"2020","unstructured":"Adrover, J. M. et al. Programmed \u2018disarming\u2019 of the neutrophil proteome reduces the magnitude of inflammation. Nat. Immunol. 21, 135\u2013144 (2020).","journal-title":"Nat. Immunol."},{"key":"2127_CR79","doi-asserted-by":"publisher","first-page":"2002384","DOI":"10.1183\/13993003.02384-2020","volume":"57","author":"L Michalick","year":"2021","unstructured":"Michalick, L. et al. Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure. Eur. Respir. J. 57, 2002384 (2021).","journal-title":"Eur. Respir. J."},{"key":"2127_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897487","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. METTL3-Mediated N6-Methyladenosine mModification of Trim59 mRNA protects against sepsis-induced acute respiratory distress syndrome. Front Immunol. 13, 897487 (2022).","journal-title":"Front Immunol."},{"key":"2127_CR81","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.phrs.2019.01.006","volume":"141","author":"S Artham","year":"2019","unstructured":"Artham, S. et al. Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury. Pharm. Res. 141, 249\u2013263 (2019).","journal-title":"Pharm. Res."},{"key":"2127_CR82","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1172\/JCI136908","volume":"130","author":"S Xiong","year":"2020","unstructured":"Xiong, S. et al. IL-1beta suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury. J. Clin. Invest. 130, 3684\u20133698 (2020).","journal-title":"J. Clin. Invest."},{"key":"2127_CR83","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/00003246-199902000-00036","volume":"27","author":"J Pugin","year":"1999","unstructured":"Pugin, J., Verghese, G., Widmer, M. C. & Matthay, M. A. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit. Care Med. 27, 304\u2013312 (1999).","journal-title":"Crit. Care Med."},{"key":"2127_CR84","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1056\/NEJM200005043421806","volume":"342","author":"LB Ware","year":"2000","unstructured":"Ware, L. B. & Matthay, M. A. The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334\u20131349 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR85","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/thoraxjnl-2012-201781","volume":"67","author":"JA Bastarache","year":"2012","unstructured":"Bastarache, J. A. et al. Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax 67, 1032\u20131039 (2012).","journal-title":"Thorax"},{"key":"2127_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-015-0086-3","volume":"3","author":"DR Janz","year":"2015","unstructured":"Janz, D. R. & Ware, L. B. The role of red blood cells and cell-free hemoglobin in the pathogenesis of ARDS. J. Intensive Care 3, 20 (2015).","journal-title":"J. Intensive Care"},{"key":"2127_CR87","doi-asserted-by":"publisher","first-page":"L88","DOI":"10.1152\/ajplung.00066.2013","volume":"306","author":"S Mumby","year":"2014","unstructured":"Mumby, S. et al. Methemoglobin-induced signaling and chemokine responses in human alveolar epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 306, L88\u2013L100 (2014).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR88","doi-asserted-by":"publisher","first-page":"C665","DOI":"10.1152\/ajpcell.00211.2022","volume":"324","author":"AK Conger","year":"2023","unstructured":"Conger, A. K. et al. Hemoglobin increases leukocyte adhesion and initiates lung microvascular endothelial activation via Toll-like receptor 4 signaling. Am. J. Physiol. Cell Physiol. 324, C665\u2013C673 (2023).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2127_CR89","doi-asserted-by":"publisher","first-page":"L29","DOI":"10.1152\/ajplung.00123.2023","volume":"326","author":"KR Schaaf","year":"2024","unstructured":"Schaaf, K. R. et al. Cell-free hemoglobin triggers macrophage cytokine production via TLR4 and MyD88. Am. J. Physiol. Lung Cell Mol. Physiol. 326, L29\u2013L38 (2024).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR90","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/CCM.0b013e3182741a54","volume":"41","author":"DR Janz","year":"2013","unstructured":"Janz, D. R. et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit. Care Med. 41, 784\u2013790 (2013).","journal-title":"Crit. Care Med."},{"key":"2127_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-023-00664-5","volume":"11","author":"V Bunger","year":"2023","unstructured":"Bunger, V. et al. Potential of cell-free hemoglobin and haptoglobin as prognostic markers in patients with ARDS and treatment with veno-venous ECMO. J. Intensive Care 11, 15 (2023).","journal-title":"J. Intensive Care"},{"key":"2127_CR92","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2024.8772","volume":"332","author":"LB Ware","year":"2024","unstructured":"Ware, L. B. et al. Acetaminophen for prevention and treatment of organ dysfunction in critically ill patients with sepsis: The ASTER randomized clinical trial. JAMA 332, 390\u2013400 (2024).","journal-title":"JAMA"},{"key":"2127_CR93","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1164\/ajrccm.163.6.2004035","volume":"163","author":"LB Ware","year":"2001","unstructured":"Ware, L. B. & Matthay, M. A. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 163, 1376\u20131383 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR94","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1164\/rccm.201403-0535OE","volume":"189","author":"MA Matthay","year":"2014","unstructured":"Matthay, M. A. Resolution of pulmonary edema. Thirty years of progress. Am. J. Respir. Crit. Care Med. 189, 1301\u20131308 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR95","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1165\/ajrcmb.25.5.4420","volume":"25","author":"ML Vivona","year":"2001","unstructured":"Vivona, M. L. et al. Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by beta-adrenergic agonist treatment. Am. J. Respir. Cell Mol. Biol. 25, 554\u2013561 (2001).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2127_CR96","doi-asserted-by":"publisher","first-page":"43939","DOI":"10.1074\/jbc.M304882200","volume":"278","author":"J Frank","year":"2003","unstructured":"Frank, J. et al. Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1\/2-dependent mechanism. J. Biol. Chem. 278, 43939\u201343950 (2003).","journal-title":"J. Biol. Chem."},{"key":"2127_CR97","doi-asserted-by":"publisher","first-page":"24109","DOI":"10.1074\/jbc.M700821200","volume":"282","author":"JW Lee","year":"2007","unstructured":"Lee, J. W. et al. Acute lung injury edema fluid decreases net fluid transport across human alveolar epithelial type II cells. J. Biol. Chem. 282, 24109\u201324119 (2007).","journal-title":"J. Biol. Chem."},{"key":"2127_CR98","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1172\/JCI11963","volume":"107","author":"JF Pittet","year":"2001","unstructured":"Pittet, J. F. et al. TGF-beta is a critical mediator of acute lung injury. J. Clin. Invest 107, 1537\u20131544 (2001).","journal-title":"J. Clin. Invest"},{"key":"2127_CR99","doi-asserted-by":"publisher","first-page":"E374","DOI":"10.1073\/pnas.1306798111","volume":"111","author":"DM Peters","year":"2014","unstructured":"Peters, D. M. et al. TGF-beta directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proc. Natl Acad. Sci. USA 111, E374\u2013E383 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2127_CR100","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1096\/fj.12-219295","volume":"27","author":"J Roux","year":"2013","unstructured":"Roux, J. et al. IL-8 inhibits cAMP-stimulated alveolar epithelial fluid transport via a GRK2\/PI3K-dependent mechanism. FASEB J. 27, 1095\u20131106 (2013).","journal-title":"FASEB J."},{"key":"2127_CR101","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nm.2736","volume":"18","author":"MN Islam","year":"2012","unstructured":"Islam, M. N. et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat. Med 18, 759\u2013765 (2012).","journal-title":"Nat. Med"},{"key":"2127_CR102","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1164\/rccm.200501-155OC","volume":"173","author":"JM Hickman-Davis","year":"2006","unstructured":"Hickman-Davis, J. M. et al. Reactive species mediate inhibition of alveolar type II sodium transport during mycoplasma infection. Am. J. Respir. Crit. Care Med 173, 334\u2013344 (2006).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR103","doi-asserted-by":"publisher","first-page":"L366","DOI":"10.1152\/ajplung.00011.2004","volume":"287","author":"XJ Chen","year":"2004","unstructured":"Chen, X. J. et al. Influenza virus inhibits ENaC and lung fluid clearance. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L366\u2013373 (2004).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR104","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1074\/jbc.M806816200","volume":"284","author":"W Song","year":"2009","unstructured":"Song, W. et al. Respiratory syncytial virus inhibits lung epithelial Na+ channels by up-regulating inducible nitric-oxide synthase. J. Biol. Chem. 284, 7294\u20137306 (2009).","journal-title":"J. Biol. Chem."},{"key":"2127_CR105","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1164\/rccm.201808-1599OC","volume":"200","author":"AJ Harris","year":"2019","unstructured":"Harris, A. J. et al. IL4Ralpha signaling abrogates Hypoxic neutrophil survival and limits acute lung injury responses in vivo. Am. J. Respir. Crit. Care Med 200, 235\u2013246 (2019).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR106","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.trsl.2021.01.008","volume":"233","author":"J Blazquez-Prieto","year":"2021","unstructured":"Blazquez-Prieto, J. et al. Activation of p21 limits acute lung injury and induces early senescence after acid aspiration and mechanical ventilation. Transl. Res. 233, 104\u2013116 (2021).","journal-title":"Transl. Res."},{"key":"2127_CR107","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41418-022-00966-5","volume":"29","author":"CG Hsu","year":"2022","unstructured":"Hsu, C. G. et al. The lipid peroxidation product 4-hydroxynonenal inhibits NLRP3 inflammasome activation and macrophage pyroptosis. Cell Death Differ. 29, 1790\u20131803 (2022).","journal-title":"Cell Death Differ."},{"key":"2127_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03775-3","volume":"25","author":"Y Jiao","year":"2021","unstructured":"Jiao, Y. et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Crit. Care 25, 356 (2021).","journal-title":"Crit. Care"},{"key":"2127_CR109","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.7150\/ijbs.66477","volume":"18","author":"X Qin","year":"2022","unstructured":"Qin, X. et al. Caspase-1-mediated extracellular vesicles derived from pyroptotic alveolar macrophages promote inflammation in acute lung injury. Int J. Biol. Sci. 18, 1521\u20131538 (2022).","journal-title":"Int J. Biol. Sci."},{"key":"2127_CR110","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/s41422-021-00519-4","volume":"31","author":"B Xia","year":"2021","unstructured":"Xia, B. et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 31, 847\u2013860 (2021).","journal-title":"Cell Res."},{"key":"2127_CR111","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.7150\/ijbs.69141","volume":"18","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Neutrophil extracellular traps mediate m(6)A modification and regulates sepsis-associated acute lung injury by activating ferroptosis in alveolar epithelial cells. Int J. Biol. Sci. 18, 3337\u20133357 (2022).","journal-title":"Int J. Biol. Sci."},{"key":"2127_CR112","doi-asserted-by":"publisher","first-page":"eabj7790","DOI":"10.1126\/scitranslmed.abj7790","volume":"13","author":"F D\u2019Agnillo","year":"2021","unstructured":"D\u2019Agnillo, F. et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. 13, eabj7790 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2127_CR113","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-021-00819-6","volume":"6","author":"L Ruhl","year":"2021","unstructured":"Ruhl, L. et al. Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. Signal Transduct. Target Ther. 6, 418 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2127_CR114","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41392-022-00953-9","volume":"7","author":"Y Qian","year":"2022","unstructured":"Qian, Y. et al. TRIM47 is a novel endothelial activation factor that aggravates lipopolysaccharide-induced acute lung injury in mice via K63-linked ubiquitination of TRAF2. Signal Transduct. Target Ther. 7, 148 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2127_CR115","doi-asserted-by":"publisher","first-page":"22351","DOI":"10.1073\/pnas.2010229117","volume":"117","author":"S Kang","year":"2020","unstructured":"Kang, S. et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc. Natl Acad. Sci. USA 117, 22351\u201322356 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2127_CR116","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1164\/rccm.202006-2388ED","volume":"202","author":"B McNicholas","year":"2020","unstructured":"McNicholas, B., Madden, M. G. & Laffey, J. G. Machine learning classifier models: the future for acute respiratory distress syndrome phenotyping? Am. J. Respir. Crit. Care Med. 202, 919\u2013920 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR117","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1136\/thoraxjnl-2017-211090","volume":"73","author":"K Delucchi","year":"2018","unstructured":"Delucchi, K. et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax 73, 439\u2013445 (2018).","journal-title":"Thorax"},{"key":"2127_CR118","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee, C. S. et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir. Med. 2, 611\u2013620 (2014).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR119","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2213-2600(21)00461-6","volume":"10","author":"MV Maddali","year":"2022","unstructured":"Maddali, M. V. et al. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir. Med. 10, 367\u2013377 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-2600(19)30369-8","volume":"8","author":"P Sinha","year":"2020","unstructured":"Sinha, P. et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir. Med. 8, 247\u2013257 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR121","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1164\/rccm.202002-0347OC","volume":"202","author":"P Sinha","year":"2020","unstructured":"Sinha, P., Churpek, M. M. & Calfee, C. S. Machine learning classifier models can identify acute respiratory distress syndrome phenotypes using readily available clinical data. Am. J. Respir. Crit. Care Med. 202, 996\u20131004 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR122","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa032193","volume":"351","author":"RG Brower","year":"2004","unstructured":"Brower, R. G. et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N. Engl. J. Med. 351, 327\u2013336 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR123","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1056\/NEJMoa062200","volume":"354","author":"L National Heart","year":"2006","unstructured":"National Heart, L. et al. Comparison of two fluid-management strategies in acute lung injury. N. Engl. J. Med. 354, 2564\u20132575 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR124","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","volume":"370","author":"L National Heart","year":"2014","unstructured":"National Heart, L. et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N. Engl. J. Med. 370, 2191\u20132200 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03734-y","volume":"25","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment. Crit. Care 25, 320 (2021).","journal-title":"Crit. Care"},{"key":"2127_CR126","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200610-1534OC","volume":"176","author":"J Villar","year":"2007","unstructured":"Villar, J. et al. An early PEEP\/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 176, 795\u2013804 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR127","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00134-012-2803-x","volume":"39","author":"J Villar","year":"2013","unstructured":"Villar, J. et al. A universal definition of ARDS: the PaO2\/FiO2 ratio under a standard ventilatory setting-a prospective, multicenter validation study. Intensive Care Med 39, 583\u2013592 (2013).","journal-title":"Intensive Care Med"},{"key":"2127_CR128","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/CCM.0000000000000703","volume":"43","author":"J Villar","year":"2015","unstructured":"Villar, J. et al. A clinical classification of the acute respiratory distress syndrome for predicting outcome and guiding medical therapy. Crit. Care Med. 43, 346\u2013353 (2015).","journal-title":"Crit. Care Med."},{"key":"2127_CR129","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00134-004-2163-2","volume":"30","author":"ND Ferguson","year":"2004","unstructured":"Ferguson, N. D. et al. Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial. Intensive Care Med. 30, 1111\u20131116 (2004).","journal-title":"Intensive Care Med."},{"key":"2127_CR130","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.chest.2018.09.031","volume":"155","author":"EJ Schenck","year":"2019","unstructured":"Schenck, E. J. et al. Rapidly improving ARDS in therapeutic randomized controlled trials. Chest 155, 474\u2013482 (2019).","journal-title":"Chest"},{"key":"2127_CR131","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12931-022-02015-8","volume":"23","author":"E Gavrielatou","year":"2022","unstructured":"Gavrielatou, E. et al. Rapidly improving acute respiratory distress syndrome in COVID-19: a multi-centre observational study. Respir. Res. 23, 94 (2022).","journal-title":"Respir. Res."},{"key":"2127_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04211-w","volume":"26","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Longitudinal phenotypes in patients with acute respiratory distress syndrome: a multi-database study. Crit. Care 26, 340 (2022).","journal-title":"Crit. Care"},{"key":"2127_CR133","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S2213-2600(20)30366-0","volume":"8","author":"P Sinha","year":"2020","unstructured":"Sinha, P. et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir. Med. 8, 1209\u20131218 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR134","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.eclinm.2021.100829","volume":"34","author":"S Ranjeva","year":"2021","unstructured":"Ranjeva, S. et al. Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019. EClinicalMedicine 34, 100829 (2021).","journal-title":"EClinicalMedicine"},{"key":"2127_CR135","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S2213-2600(21)00365-9","volume":"9","author":"LDJ Bos","year":"2021","unstructured":"Bos, L. D. J. et al. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respir. Med. 9, 1377\u20131386 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR136","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00134-020-06033-2","volume":"46","author":"L Gattinoni","year":"2020","unstructured":"Gattinoni, L. et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 46, 1099\u20131102 (2020).","journal-title":"Intensive Care Med."},{"key":"2127_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03414-3","volume":"24","author":"F Perier","year":"2020","unstructured":"Perier, F. et al. Electrical impedance tomography to titrate positive end-expiratory pressure in COVID-19 acute respiratory distress syndrome. Crit. Care 24, 678 (2020).","journal-title":"Crit. Care"},{"key":"2127_CR138","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.trsl.2015.08.004","volume":"167","author":"AL Durham","year":"2016","unstructured":"Durham, A. L., Caramori, G., Chung, K. F. & Adcock, I. M. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl. Res. 167, 192\u2013203 (2016).","journal-title":"Transl. Res."},{"key":"2127_CR139","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ctrv.2015.02.008","volume":"41","author":"SL Wood","year":"2015","unstructured":"Wood, S. L., Pernemalm, M., Crosbie, P. A. & Whetton, A. D. Molecular histology of lung cancer: from targets to treatments. Cancer Treat. Rev. 41, 361\u2013375 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"2127_CR140","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/thoraxjnl-2016-209719","volume":"72","author":"LD Bos","year":"2017","unstructured":"Bos, L. D. et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax 72, 876\u2013883 (2017).","journal-title":"Thorax"},{"key":"2127_CR141","doi-asserted-by":"publisher","first-page":"48s","DOI":"10.1183\/09031936.03.00420803","volume":"42","author":"P Pelosi","year":"2003","unstructured":"Pelosi, P. et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur. Respir. J. Suppl. 42, 48s\u201356s (2003).","journal-title":"Eur. Respir. J. Suppl."},{"key":"2127_CR142","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1378\/chest.14-2454","volume":"147","author":"CS Calfee","year":"2015","unstructured":"Calfee, C. S. et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest 147, 1539\u20131548 (2015).","journal-title":"Chest"},{"key":"2127_CR143","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1164\/rccm.202005-1916OC","volume":"204","author":"K Peukert","year":"2021","unstructured":"Peukert, K. et al. Inhibition of Caspase-1 with Tetracycline ameliorates acute lung injury. Am. J. Respir. Crit. Care Med. 204, 53\u201363 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR144","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/CCM.0000000000001611","volume":"44","author":"CS Samary","year":"2016","unstructured":"Samary, C. S. et al. Lung functional and biologic responses to variable ventilation in experimental pulmonary and extrapulmonary acute respiratory distress Syndrome. Crit. Care Med. 44, e553\u2013e562 (2016).","journal-title":"Crit. Care Med."},{"key":"2127_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0474-4","volume":"18","author":"L Moraes","year":"2014","unstructured":"Moraes, L. et al. Effects of sigh during pressure control and pressure support ventilation in pulmonary and extrapulmonary mild acute lung injury. Crit. Care. 18, 474 (2014).","journal-title":"Crit. Care."},{"key":"2127_CR146","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1164\/rccm.201809-1808OC","volume":"200","author":"LDJ Bos","year":"2019","unstructured":"Bos, L. D. J. et al. Understanding heterogeneity in biologic phenotypes of acute respiratory distress Syndrome by leukocyte expression profiles. Am. J. Respir. Crit. Care Med 200, 42\u201350 (2019).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR147","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee, C. S. et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir. Med. 6, 691\u2013698 (2018).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR148","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1167\/iovs.12-9658","volume":"53","author":"KJ Kim","year":"2012","unstructured":"Kim, K. J., Kim, K. S., Kim, N. R. & Chin, H. S. Effects of simvastatin on the expression of heme oxygenase-1 in human RPE cells. Invest Ophthalmol. Vis. Sci. 53, 6456\u20136464 (2012).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"2127_CR149","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/cbf.1654","volume":"28","author":"V Manfredini","year":"2010","unstructured":"Manfredini, V. et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem. Funct. 28, 360\u2013366 (2010).","journal-title":"Cell Biochem. Funct."},{"key":"2127_CR150","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/thoraxjnl-2021-216904","volume":"77","author":"M Griffiths","year":"2022","unstructured":"Griffiths, M. et al. RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic. Thorax 77, 129\u2013135 (2022).","journal-title":"Thorax"},{"key":"2127_CR151","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1164\/rccm.202311-2011ST","volume":"209","author":"N Qadir","year":"2024","unstructured":"Qadir, N. et al. An update on management of adult patients with acute respiratory distress syndrome: An Official American Thoracic Society Clinical Practice Guideline. Am. J. Respir. Crit. Care Med 209, 24\u201336 (2024).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR152","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","volume":"49","author":"G Grasselli","year":"2023","unstructured":"Grasselli, G. et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 49, 727\u2013759 (2023).","journal-title":"Intensive Care Med."},{"key":"2127_CR153","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.resinv.2022.05.003","volume":"60","author":"S Tasaka","year":"2022","unstructured":"Tasaka, S. et al. ARDS clinical practice guideline 2021. Respir. Investig. 60, 446\u2013495 (2022).","journal-title":"Respir. Investig."},{"key":"2127_CR154","doi-asserted-by":"publisher","first-page":"735","DOI":"10.4187\/respcare.06718","volume":"64","author":"M Nishimura","year":"2019","unstructured":"Nishimura, M. High-flow nasal cannula oxygen therapy devices. Respir. Care 64, 735\u2013742 (2019).","journal-title":"Respir. Care"},{"key":"2127_CR155","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s00134-020-06312-y","volume":"46","author":"B Rochwerg","year":"2020","unstructured":"Rochwerg, B. et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Med. 46, 2226\u20132237 (2020).","journal-title":"Intensive Care Med."},{"key":"2127_CR156","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1164\/rccm.201706-1244OC","volume":"197","author":"CCA Morais","year":"2018","unstructured":"Morais, C. C. A. et al. High positive end-expiratory pressure renders spontaneous effort noninjurious. Am. J. Respir. Crit. Care Med. 197, 1285\u20131296 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR157","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.2016.6338","volume":"315","author":"BK Patel","year":"2016","unstructured":"Patel, B. K. et al. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 315, 2435\u20132441 (2016).","journal-title":"JAMA"},{"key":"2127_CR158","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jama.2021.4682","volume":"325","author":"DL Grieco","year":"2021","unstructured":"Grieco, D. L. et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: The HENIVOT randomized clinical trial. JAMA 325, 1731\u20131743 (2021).","journal-title":"JAMA"},{"key":"2127_CR159","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","volume":"342","author":"N Acute Respiratory Distress Syndrome","year":"2000","unstructured":"Acute Respiratory Distress Syndrome, N. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 342, 1301\u20131308 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR160","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMsa1410639","volume":"372","author":"MB Amato","year":"2015","unstructured":"Amato, M. B. et al. Driving pressure and survival in the acute respiratory distress syndrome. N. Engl. J. Med. 372, 747\u2013755 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR161","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1164\/rccm.202009-3467OC","volume":"204","author":"ELV Costa","year":"2021","unstructured":"Costa, E. L. V. et al. Ventilatory variables and mechanical power in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 204, 303\u2013311 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR162","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1164\/rccm.202104-0839ED","volume":"204","author":"JR Beitler","year":"2021","unstructured":"Beitler, J. R. & Walkey, A. J. The staying power of pressure- and volume-limited ventilation in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 204, 247\u2013249 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR163","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF01694358","volume":"18","author":"B Lachmann","year":"1992","unstructured":"Lachmann, B. Open up the lung and keep the lung open. Intensive Care Med 18, 319\u2013321 (1992).","journal-title":"Intensive Care Med"},{"key":"2127_CR164","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.299.6.646","volume":"299","author":"A Mercat","year":"2008","unstructured":"Mercat, A. et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299, 646\u2013655 (2008).","journal-title":"JAMA"},{"key":"2127_CR165","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.299.6.637","volume":"299","author":"MO Meade","year":"2008","unstructured":"Meade, M. O. et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299, 637\u2013645 (2008).","journal-title":"JAMA"},{"key":"2127_CR166","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jama.2017.14171","volume":"318","author":"Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial, I.","year":"2017","unstructured":"Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial, I. et al. Effect of lung recruitment and titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 318, 1335\u20131345 (2017).","journal-title":"JAMA"},{"key":"2127_CR167","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1164\/rccm.201404-0688OC","volume":"190","author":"EC Goligher","year":"2014","unstructured":"Goligher, E. C. et al. Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials. Am. J. Respir. Crit. Care Med. 190, 70\u201376 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR168","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2019.0555","volume":"321","author":"JR Beitler","year":"2019","unstructured":"Beitler, J. R. et al. Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 321, 846\u2013857 (2019).","journal-title":"JAMA"},{"key":"2127_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1446-7","volume":"20","author":"D Chiumello","year":"2016","unstructured":"Chiumello, D., Carlesso, E., Brioni, M. & Cressoni, M. Airway driving pressure and lung stress in ARDS patients. Crit. Care 20, 276 (2016).","journal-title":"Crit. Care"},{"key":"2127_CR170","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/cvr\/21.9.660","volume":"21","author":"M Nanki","year":"1987","unstructured":"Nanki, M. et al. Evaluation of the effect of metoprolol on energy metabolism in the ischaemic myocardium in relation to regional myocardial blood flow. Cardiovasc. Res. 21, 660\u2013667 (1987).","journal-title":"Cardiovasc. Res."},{"key":"2127_CR171","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1164\/rccm.201908-1545CI","volume":"201","author":"JJ Marini","year":"2020","unstructured":"Marini, J. J., Rocco, P. R. M. & Gattinoni, L. Static and dynamic contributors to ventilator-induced lung injury in clinical practice. pressure, energy, and power. Am. J. Respir. Crit. Care Med. 201, 767\u2013774 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR172","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/ALN.0000000000001056","volume":"124","author":"M Cressoni","year":"2016","unstructured":"Cressoni, M. et al. Mechanical power and development of ventilator-induced lung injury. Anesthesiology 124, 1100\u20131108 (2016).","journal-title":"Anesthesiology"},{"key":"2127_CR173","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00134-016-4505-2","volume":"42","author":"L Gattinoni","year":"2016","unstructured":"Gattinoni, L. et al. Ventilator-related causes of lung injury: the mechanical power. Intensive Care Med 42, 1567\u20131575 (2016).","journal-title":"Intensive Care Med"},{"key":"2127_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03853-6","volume":"26","author":"AK Bhalla","year":"2022","unstructured":"Bhalla, A. K. et al. Mechanical power in pediatric acute respiratory distress syndrome: a PARDIE study. Crit. Care 26, 2 (2022).","journal-title":"Crit. Care"},{"key":"2127_CR175","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02963-x","volume":"24","author":"S Coppola","year":"2020","unstructured":"Coppola, S. et al. Effect of mechanical power on intensive care mortality in ARDS patients. Crit. Care 24, 246 (2020).","journal-title":"Crit. Care"},{"key":"2127_CR176","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1007\/s00134-018-5375-6","volume":"44","author":"A Serpa Neto","year":"2018","unstructured":"Serpa Neto, A. et al. Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts. Intensive Care Med. 44, 1914\u20131922 (2018).","journal-title":"Intensive Care Med."},{"key":"2127_CR177","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1164\/ajrccm.149.1.8111603","volume":"149","author":"P Pelosi","year":"1994","unstructured":"Pelosi, P. et al. Vertical gradient of regional lung inflation in adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med 149, 8\u201313 (1994).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR178","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00000542-199101000-00004","volume":"74","author":"L Gattinoni","year":"1991","unstructured":"Gattinoni, L. et al. Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure. Anesthesiology 74, 15\u201323 (1991).","journal-title":"Anesthesiology"},{"key":"2127_CR179","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1056\/NEJMoa052052","volume":"354","author":"L Gattinoni","year":"2006","unstructured":"Gattinoni, L. et al. Lung recruitment in patients with the acute respiratory distress syndrome. N. Engl. J. Med 354, 1775\u20131786 (2006).","journal-title":"N. Engl. J. Med"},{"key":"2127_CR180","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2009.1614","volume":"302","author":"P Taccone","year":"2009","unstructured":"Taccone, P. et al. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA 302, 1977\u20131984 (2009).","journal-title":"JAMA"},{"key":"2127_CR181","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1001\/jama.292.19.2379","volume":"292","author":"C Guerin","year":"2004","unstructured":"Guerin, C. et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA 292, 2379\u20132387 (2004).","journal-title":"JAMA"},{"key":"2127_CR182","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1164\/rccm.201308-1532CI","volume":"188","author":"L Gattinoni","year":"2013","unstructured":"Gattinoni, L., Taccone, P., Carlesso, E. & Marini, J. J. Prone position in acute respiratory distress syndrome. Rationale, indications, and limits. Am. J. Respir. Crit. Care Med. 188, 1286\u20131293 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR183","doi-asserted-by":"publisher","first-page":"E381","DOI":"10.1503\/cmaj.140081","volume":"186","author":"S Sud","year":"2014","unstructured":"Sud, S. et al. Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 186, E381\u2013E390 (2014).","journal-title":"CMAJ"},{"key":"2127_CR184","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","volume":"368","author":"C Guerin","year":"2013","unstructured":"Guerin, C. et al. Prone positioning in severe acute respiratory distress syndrome. N. Engl. J. Med. 368, 2159\u20132168 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR185","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S2213-2600(20)30268-X","volume":"8","author":"A Coppo","year":"2020","unstructured":"Coppo, A. et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir. Med. 8, 765\u2013774 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR186","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jamainternmed.2020.3030","volume":"180","author":"AE Thompson","year":"2020","unstructured":"Thompson, A. E., Ranard, B. L., Wei, Y. & Jelic, S. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. JAMA Intern. Med. 180, 1537\u20131539 (2020).","journal-title":"JAMA Intern. Med."},{"key":"2127_CR187","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1001\/jama.2022.7993","volume":"327","author":"W Alhazzani","year":"2022","unstructured":"Alhazzani, W. et al. Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial. JAMA 327, 2104\u20132113 (2022).","journal-title":"JAMA"},{"key":"2127_CR188","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S2213-2600(21)00356-8","volume":"9","author":"S Ehrmann","year":"2021","unstructured":"Ehrmann, S. et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir. Med 9, 1387\u20131395 (2021).","journal-title":"Lancet Respir. Med"},{"key":"2127_CR189","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/CCM.0000000000005145","volume":"50","author":"M Petit","year":"2022","unstructured":"Petit, M. et al. Prone-positioning for severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation. Crit. Care Med. 50, 264\u2013274 (2022).","journal-title":"Crit. Care Med."},{"key":"2127_CR190","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1001\/jama.2023.24491","volume":"330","author":"M Schmidt","year":"2023","unstructured":"Schmidt, M. et al. Prone positioning during extracorporeal membrane oxygenation in patients with severe ARDS: The PRONECMO randomized clinical trial. JAMA 330, 2343\u20132353 (2023).","journal-title":"JAMA"},{"key":"2127_CR191","doi-asserted-by":"publisher","first-page":"S280","DOI":"10.1513\/AnnalsATS.201704-343OT","volume":"14","author":"L Munshi","year":"2017","unstructured":"Munshi, L. et al. Prone position for acute respiratory distress syndrome. a systematic review and meta-analysis. Ann. Am. Thorac. Soc. 14, S280\u2013S288 (2017).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2127_CR192","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.chest.2022.05.009","volume":"162","author":"G Rampon","year":"2022","unstructured":"Rampon, G. et al. Smartphone-guided self-prone positioning vs usual care in nonintubated hospital ward patients with COVID-19: A pragmatic randomized clinical trial. Chest 162, 782\u2013791 (2022).","journal-title":"Chest"},{"key":"2127_CR193","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2213-2600(22)00043-1","volume":"10","author":"J Li","year":"2022","unstructured":"Li, J. et al. Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis. Lancet Respir. Med. 10, 573\u2013583 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR194","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4187\/respcare.07849","volume":"66","author":"H Torbic","year":"2021","unstructured":"Torbic, H., Krishnan, S., Harnegie, M. P. & Duggal, A. Neuromuscular blocking agents for ARDS: A systematic review and meta-analysis. Respir. Care 66, 120\u2013128 (2021).","journal-title":"Respir. Care"},{"key":"2127_CR195","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1005372","volume":"363","author":"L Papazian","year":"2010","unstructured":"Papazian, L. et al. Neuromuscular blockers in early acute respiratory distress syndrome. N. Engl. J. Med. 363, 1107\u20131116 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR196","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1056\/NEJMoa1901686","volume":"380","author":"L National Heart","year":"2019","unstructured":"National Heart, L. et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N. Engl. J. Med. 380, 1997\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR197","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1001\/jama.289.22.2983","volume":"289","author":"EW Ely","year":"2003","unstructured":"Ely, E. W. et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 289, 2983\u20132991 (2003).","journal-title":"JAMA"},{"key":"2127_CR198","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(09)61069-2","volume":"374","author":"GJ Peek","year":"2009","unstructured":"Peek, G. J. et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 374, 1351\u20131363 (2009).","journal-title":"Lancet"},{"key":"2127_CR199","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1056\/NEJMoa1800385","volume":"378","author":"A Combes","year":"2018","unstructured":"Combes, A. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N. Engl. J. Med. 378, 1965\u20131975 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR200","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2018.14276","volume":"320","author":"EC Goligher","year":"2018","unstructured":"Goligher, E. C. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA 320, 2251\u20132259 (2018).","journal-title":"JAMA"},{"key":"2127_CR201","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1007\/s00134-020-06248-3","volume":"46","author":"A Combes","year":"2020","unstructured":"Combes, A. et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med. 46, 2048\u20132057 (2020).","journal-title":"Intensive Care Med."},{"key":"2127_CR202","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2213-2600(20)30581-6","volume":"9","author":"L Camporota","year":"2021","unstructured":"Camporota, L. et al. Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service. Lancet Respir. Med. 9, e16\u2013e17 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR203","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jama.2021.13374","volume":"326","author":"JJ McNamee","year":"2021","unstructured":"McNamee, J. J. et al. Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: The REST randomized clinical trial. JAMA 326, 1013\u20131023 (2021).","journal-title":"JAMA"},{"key":"2127_CR204","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1164\/rccm.202111-2495OC","volume":"206","author":"D Hajage","year":"2022","unstructured":"Hajage, D. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: An emulated target trial analysis. Am. J. Respir. Crit. Care Med. 206, 281\u2013294 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR205","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068723","volume":"377","author":"M Urner","year":"2022","unstructured":"Urner, M. et al. Venovenous extracorporeal membrane oxygenation in patients with acute COVID-19 associated respiratory failure: comparative effectiveness study. BMJ 377, e068723 (2022).","journal-title":"BMJ"},{"key":"2127_CR206","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1164\/rccm.201404-0630CP","volume":"190","author":"A Combes","year":"2014","unstructured":"Combes, A. et al. Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. Am. J. Respir. Crit. Care Med. 190, 488\u2013496 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR207","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa051693","volume":"354","author":"KP Steinberg","year":"2006","unstructured":"Steinberg, K. P. et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 354, 1671\u20131684 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR208","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","volume":"8","author":"J Villar","year":"2020","unstructured":"Villar, J. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. 8, 267\u2013276 (2020).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR209","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00134-021-06394-2","volume":"47","author":"D Chaudhuri","year":"2021","unstructured":"Chaudhuri, D. et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 47, 521\u2013537 (2021).","journal-title":"Intensive Care Med."},{"key":"2127_CR210","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med"},{"key":"2127_CR211","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group,","year":"2020","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al.Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 324, 1330\u20131341 (2020).","journal-title":"JAMA"},{"key":"2127_CR212","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00134-018-5332-4","volume":"44","author":"G Moreno","year":"2018","unstructured":"Moreno, G. et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 44, 1470\u20131482 (2018).","journal-title":"Intensive Care Med."},{"key":"2127_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118600","volume":"263","author":"S Sadeghian Chaleshtori","year":"2020","unstructured":"Sadeghian Chaleshtori, S. et al. Prevention of LPS-induced acute respiratory distress syndrome in sheep by bone marrow-derived mesenchymal stem\/stromal cells. Life Sci. 263, 118600 (2020).","journal-title":"Life Sci."},{"key":"2127_CR214","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/scrt430","volume":"5","author":"M Rojas","year":"2014","unstructured":"Rojas, M. et al. Human adult bone marrow-derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress syndrome in sheep. Stem Cell Res. Ther. 5, 42 (2014).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR215","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson, J. G. et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 3, 24\u201332 (2015).","journal-title":"Lancet Respir. Med"},{"key":"2127_CR216","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1097\/CCM.0000000000002833","volume":"46","author":"JD Silva","year":"2018","unstructured":"Silva, J. D. et al. Mesenchymal stem cells from bone marrow, adipose tissue, and lung tissue differentially mitigate lung and distal organ damage in experimental acute respiratory distress syndrome. Crit. Care Med 46, e132\u2013e140 (2018).","journal-title":"Crit. Care Med"},{"key":"2127_CR217","doi-asserted-by":"publisher","first-page":"BSR20171301","DOI":"10.1042\/BSR20171301","volume":"37","author":"M Kasper","year":"2017","unstructured":"Kasper, M. & Barth, K. Potential contribution of alveolar epithelial type I cells to pulmonary fibrosis. Biosci. Rep. 37, BSR20171301 (2017).","journal-title":"Biosci. Rep."},{"key":"2127_CR218","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12931-016-0480-y","volume":"17","author":"L Zeng","year":"2016","unstructured":"Zeng, L. et al. The cellular kinetics of lung alveolar epithelial cells and its relationship with lung tissue repair after acute lung injury. Respir. Res. 17, 164 (2016).","journal-title":"Respir. Res"},{"key":"2127_CR219","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.ajpath.2019.04.014","volume":"189","author":"X Huang","year":"2019","unstructured":"Huang, X. et al. Endothelial Hypoxia-Inducible Factor-1alpha is required for vascular repair and resolution of inflammatory lung injury through Forkhead Box Protein M1. Am. J. Pathol. 189, 1664\u20131679 (2019).","journal-title":"Am. J. Pathol."},{"key":"2127_CR220","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1084\/jem.20102041","volume":"208","author":"Y Liu","year":"2011","unstructured":"Liu, Y. et al. FoxM1 mediates the progenitor function of type II epithelial cells in repairing alveolar injury induced by Pseudomonas aeruginosa. J. Exp. Med. 208, 1473\u20131484 (2011).","journal-title":"J. Exp. Med."},{"key":"2127_CR221","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8324504","volume":"2023","author":"Y Luo","year":"2023","unstructured":"Luo, Y. et al. Overexpression of FoxM1 enhanced the protective effect of bone marrow-derived mesenchymal stem cells on lipopolysaccharide-induced acute lung injury through the activation of Wnt\/beta-Catenin signaling. Oxid. Med. Cell Longev. 2023, 8324504 (2023).","journal-title":"Oxid. Med. Cell Longev."},{"key":"2127_CR222","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13287-023-03240-8","volume":"14","author":"Y Luo","year":"2023","unstructured":"Luo, Y. et al. Overexpression of FoxM1 optimizes the therapeutic effect of bone marrow mesenchymal stem cells on acute respiratory distress syndrome. Stem Cell Res. Ther. 14, 27 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR223","doi-asserted-by":"publisher","first-page":"114302","DOI":"10.1016\/j.biopha.2023.114302","volume":"159","author":"XY Chen","year":"2023","unstructured":"Chen, X. Y. et al. YAP-regulated type II alveolar epithelial cell differentiation mediated by human umbilical cord-derived mesenchymal stem cells in acute respiratory distress syndrome. Biomed. Pharmacother. 159, 114302 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2127_CR224","first-page":"1241","volume":"43","author":"L Li","year":"2019","unstructured":"Li, L. et al. Mesenchymal stem cells with downregulated Hippo signaling attenuate lung injury in mice with lipopolysaccharide\u2011induced acute respiratory distress syndrome. Int. J. Mol. Med. 43, 1241\u20131252 (2019).","journal-title":"Int. J. Mol. Med."},{"key":"2127_CR225","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/ncb3496","volume":"19","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q. et al. Hippo signalling governs cytosolic nucleic acid sensing through YAP\/TAZ-mediated TBK1 blockade. Nat. Cell Biol. 19, 362\u2013374 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2127_CR226","doi-asserted-by":"publisher","first-page":"e90229","DOI":"10.1371\/journal.pone.0090229","volume":"9","author":"A Liu","year":"2014","unstructured":"Liu, A. et al. Wnt5a through noncanonical Wnt\/JNK or Wnt\/PKC signaling contributes to the differentiation of mesenchymal stem cells into type II alveolar epithelial cells in vitro. PLoS One 9, e90229 (2014).","journal-title":"PLoS One"},{"key":"2127_CR227","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3727\/096368915X689776","volume":"25","author":"SX Cai","year":"2016","unstructured":"Cai, S. X. et al. The orphan receptor Tyrosine Kinase ROR2 facilitates MSCs to repair lung injury in ARDS animal model. Cell Transpl. 25, 1561\u20131574 (2016).","journal-title":"Cell Transpl."},{"key":"2127_CR228","doi-asserted-by":"publisher","first-page":"9992381","DOI":"10.1155\/2021\/9992381","volume":"2021","author":"K Wang","year":"2021","unstructured":"Wang, K. et al. Vimentin-Rab7a pathway mediates the migration of MSCs and lead to therapeutic effects on ARDS. Stem Cells Int. 2021, 9992381 (2021).","journal-title":"Stem Cells Int."},{"key":"2127_CR229","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13287-019-1488-2","volume":"10","author":"Z Lu","year":"2019","unstructured":"Lu, Z. et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. Stem Cell Res. Ther. 10, 372 (2019).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR230","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02410-z","volume":"18","author":"Z Lu","year":"2020","unstructured":"Lu, Z. et al. Mesenchymal stem cells activate Notch signaling to induce regulatory dendritic cells in LPS-induced acute lung injury. J. Transl. Med. 18, 241 (2020).","journal-title":"J. Transl. Med."},{"key":"2127_CR231","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13287-023-03277-9","volume":"14","author":"K Hezam","year":"2023","unstructured":"Hezam, K. et al. Superior protective effects of PGE2 priming mesenchymal stem cells against LPS-induced acute lung injury (ALI) through macrophage immunomodulation. Stem Cell Res. Ther. 14, 48 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR232","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/sctm.18-0236","volume":"8","author":"AL Xu","year":"2019","unstructured":"Xu, A. L. et al. Mesenchymal stem cells reconditioned in their own serum exhibit augmented therapeutic properties in the setting of acute respiratory distress syndrome. Stem Cells Transl. Med 8, 1092\u20131106 (2019).","journal-title":"Stem Cells Transl. Med"},{"key":"2127_CR233","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1080\/21655979.2022.2052652","volume":"13","author":"X He","year":"2022","unstructured":"He, X. et al. Mesenchymal stem cells inhibited the apoptosis of alveolar epithelial cells caused by ARDS through CXCL12\/CXCR4 axis. Bioengineered 13, 9060\u20139070 (2022).","journal-title":"Bioengineered"},{"key":"2127_CR234","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3390\/ijms20092208","volume":"20","author":"VY Su","year":"2019","unstructured":"Su, V. Y., Lin, C. S., Hung, S. C. & Yang, K. Y. Mesenchymal stem cell-conditioned medium induces neutrophil apoptosis associated with inhibition of the NF-kappaB pathway in Endotoxin-induced acute lung injury. Int. J. Mol. Sci. 20, 2208 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2127_CR235","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.1002\/jcp.27488","volume":"234","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats. J. Cell Physiol. 234, 7301\u20137319 (2019).","journal-title":"J. Cell Physiol."},{"key":"2127_CR236","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000308","volume":"6","author":"N Cardenes","year":"2019","unstructured":"Cardenes, N. et al. Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model. BMJ Open Respir. Res. 6, e000308 (2019).","journal-title":"BMJ Open Respir. Res."},{"key":"2127_CR237","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.201802-0356OC","volume":"199","author":"D Islam","year":"2019","unstructured":"Islam, D. et al. Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury. Am. J. Respir. Crit. Care Med 199, 1214\u20131224 (2019).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR238","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/thoraxjnl-2019-213561","volume":"75","author":"N Younes","year":"2020","unstructured":"Younes, N. et al. Mesenchymal stromal\/stem cells modulate response to experimental sepsis-induced lung injury via regulation of miR-27a-5p in recipient mice. Thorax 75, 556\u2013567 (2020).","journal-title":"Thorax"},{"key":"2127_CR239","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13287-021-02245-5","volume":"12","author":"M Florian","year":"2021","unstructured":"Florian, M. et al. Gene engineered mesenchymal stem cells: greater transgene expression and efficacy with minicircle vs. plasmid DNA vectors in a mouse model of acute lung injury. Stem Cell Res. Ther. 12, 184 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR240","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13287-016-0320-5","volume":"7","author":"S Hu","year":"2016","unstructured":"Hu, S. et al. The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo. Stem Cell Res. Ther. 7, 66 (2016).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR241","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9981589","volume":"2021","author":"SS Meng","year":"2021","unstructured":"Meng, S. S. et al. mTORC2 activation mediated by mesenchymal stem cell-secreted hepatocyte growth factors for the recovery of lipopolysaccharide-induced vascular endothelial barrier. Stem Cells Int 2021, 9981589 (2021).","journal-title":"Stem Cells Int"},{"key":"2127_CR242","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/pharmaceutics13081264","volume":"13","author":"M Ishii","year":"2021","unstructured":"Ishii, M. et al. Increased in vitro intercellular barrier function of lung epithelial cells using Adipose-derived mesenchymal stem\/stromal cells. Pharmaceutics 13, 1264 (2021).","journal-title":"Pharmaceutics"},{"key":"2127_CR243","doi-asserted-by":"publisher","first-page":"8861407","DOI":"10.1155\/2020\/8861407","volume":"2020","author":"JZ Li","year":"2020","unstructured":"Li, J. Z. et al. Mechanically stretched mesenchymal stem cells can reduce the effects of LPS-induced injury on the pulmonary microvascular endothelium barrier. Stem Cells Int. 2020, 8861407 (2020).","journal-title":"Stem Cells Int."},{"key":"2127_CR244","doi-asserted-by":"publisher","first-page":"L809","DOI":"10.1152\/ajplung.00358.2013","volume":"306","author":"DF McAuley","year":"2014","unstructured":"McAuley, D. F. et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am. J. Physiol. Lung Cell Mol. Physiol. 306, L809\u2013L815 (2014).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR245","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/ajt.13271","volume":"15","author":"S Gennai","year":"2015","unstructured":"Gennai, S. et al. Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am. J. Transplant. 15, 2404\u20132412 (2015).","journal-title":"Am. J. Transplant."},{"key":"2127_CR246","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1097\/CCM.0000000000004285","volume":"48","author":"HK Yip","year":"2020","unstructured":"Yip, H. K. et al. Human Umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit. Care Med 48, e391\u2013e399 (2020).","journal-title":"Crit. Care Med"},{"key":"2127_CR247","doi-asserted-by":"publisher","first-page":"e148983","DOI":"10.1172\/jci.insight.148983","volume":"6","author":"KD Wick","year":"2021","unstructured":"Wick, K. D. et al. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight 6, e148983 (2021).","journal-title":"JCI Insight"},{"key":"2127_CR248","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1164\/rccm.202003-0544LE","volume":"202","author":"OE Simonson","year":"2020","unstructured":"Simonson, O. E. et al. Five-year follow-up after mesenchymal stromal cell-based treatment of severe acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 202, 1051\u20131055 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR249","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.5966\/sctm.2015-0021","volume":"4","author":"OE Simonson","year":"2015","unstructured":"Simonson, O. E. et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl. Med. 4, 1199\u20131213 (2015).","journal-title":"Stem Cells Transl. Med."},{"key":"2127_CR250","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3346\/jkms.2014.29.3.438","volume":"29","author":"Y Chang","year":"2014","unstructured":"Chang, Y. et al. Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome. J. Korean Med. Sci. 29, 438\u2013440 (2014).","journal-title":"J. Korean Med. Sci."},{"key":"2127_CR251","doi-asserted-by":"publisher","first-page":"101167","DOI":"10.1016\/j.eclinm.2021.101167","volume":"41","author":"E Gorman","year":"2021","unstructured":"Gorman, E. et al. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. EClinicalMedicine 41, 101167 (2021).","journal-title":"EClinicalMedicine"},{"key":"2127_CR252","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-15-39","volume":"15","author":"G Zheng","year":"2014","unstructured":"Zheng, G. et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir. Res. 15, 39 (2014).","journal-title":"Respir. Res."},{"key":"2127_CR253","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","volume":"7","author":"MA Matthay","year":"2019","unstructured":"Matthay, M. A. et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir. Med. 7, 154\u2013162 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR254","doi-asserted-by":"publisher","first-page":"932360","DOI":"10.3389\/fimmu.2022.932360","volume":"13","author":"C Gregoire","year":"2022","unstructured":"Gregoire, C. et al. Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: Preliminary results of a Phase I\/II clinical trial. Front Immunol. 13, 932360 (2022).","journal-title":"Front Immunol."},{"key":"2127_CR255","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","volume":"10","author":"G Lanzoni","year":"2021","unstructured":"Lanzoni, G. et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1\/2a, randomized controlled trial. Stem Cells Transl. Med. 10, 660\u2013673 (2021).","journal-title":"Stem Cells Transl. Med."},{"key":"2127_CR256","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jcyt.2022.03.006","volume":"24","author":"SA Whittaker Brown","year":"2022","unstructured":"Whittaker Brown, S. A. et al. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019. Cytotherapy 24, 835\u2013840 (2022).","journal-title":"Cytotherapy"},{"key":"2127_CR257","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-03930-4","volume":"26","author":"A Monsel","year":"2022","unstructured":"Monsel, A. et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit. Care 26, 48 (2022).","journal-title":"Crit. Care"},{"key":"2127_CR258","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13287-022-02953-6","volume":"13","author":"HR Aghayan","year":"2022","unstructured":"Aghayan, H. R. et al. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Stem Cell Res. Ther. 13, 365 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR259","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13287-021-02165-4","volume":"12","author":"SR Hashemian","year":"2021","unstructured":"Hashemian, S. R. et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res. Ther. 12, 91 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR260","first-page":"4435","volume":"25","author":"D Kouroupis","year":"2021","unstructured":"Kouroupis, D. et al. Umbilical cord-derived mesenchymal stem cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients. Eur. Rev. Med Pharm. Sci. 25, 4435\u20134438 (2021).","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"2127_CR261","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.3390\/ijms24054435","volume":"24","author":"T Bukreieva","year":"2023","unstructured":"Bukreieva, T. et al. Treatment of acute respiratory distress syndrome caused by COVID-19 with human umbilical cord mesenchymal stem cells. Int. J. Mol. Sci. 24, 4435 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2127_CR262","doi-asserted-by":"publisher","first-page":"360","DOI":"10.14336\/AD.2020.1218","volume":"12","author":"M Iglesias","year":"2021","unstructured":"Iglesias, M. et al. Mesenchymal stem cells for the compassionate treatment of severe acute respiratory distress Syndrome Due to COVID 19. Aging Dis. 12, 360\u2013370 (2021).","journal-title":"Aging Dis."},{"key":"2127_CR263","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/sctm.21-0046","volume":"10","author":"IH Dilogo","year":"2021","unstructured":"Dilogo, I. H. et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl. Med. 10, 1279\u20131287 (2021).","journal-title":"Stem Cells Transl. Med."},{"key":"2127_CR264","doi-asserted-by":"publisher","first-page":"871828","DOI":"10.3389\/fimmu.2022.871828","volume":"13","author":"MC Chen","year":"2022","unstructured":"Chen, M. C. et al. pcMSC modulates immune dysregulation in patients with COVID-19-induced refractory acute lung injury. Front Immunol. 13, 871828 (2022).","journal-title":"Front Immunol."},{"key":"2127_CR265","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","volume":"207","author":"ME Bowdish","year":"2023","unstructured":"Bowdish, M. E. et al. A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19. Am. J. Respir. Crit. Care Med. 207, 261\u2013270 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR266","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-022-02920-1","volume":"13","author":"N Kaffash Farkhad","year":"2022","unstructured":"Kaffash Farkhad, N. et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res. Ther. 13, 283 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR267","doi-asserted-by":"publisher","first-page":"10554","DOI":"10.1111\/jcmm.16986","volume":"25","author":"B Sadeghi","year":"2021","unstructured":"Sadeghi, B. et al. Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. J. Cell Mol. Med. 25, 10554\u201310564 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"2127_CR268","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.healun.2017.10.025","volume":"37","author":"R Guillamat-Prats","year":"2018","unstructured":"Guillamat-Prats, R. et al. Intratracheal instillation of alveolar type II cells enhances recovery from acute lung injury in rats. J. Heart Lung Transpl. 37, 782\u2013791 (2018).","journal-title":"J. Heart Lung Transpl."},{"key":"2127_CR269","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/cells9081816","volume":"9","author":"R Guillamat-Prats","year":"2020","unstructured":"Guillamat-Prats, R. et al. Alveolar Type II cells or mesenchymal stem cells: comparison of two different cell therapies for the treatment of acute lung injury in rats. Cells 9, 1816 (2020).","journal-title":"Cells"},{"key":"2127_CR270","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41422-020-0354-1","volume":"30","author":"J Wu","year":"2020","unstructured":"Wu, J. et al. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res. 30, 794\u2013809 (2020).","journal-title":"Cell Res."},{"key":"2127_CR271","first-page":"61","volume":"9","author":"Q Hu","year":"2022","unstructured":"Hu, Q. et al. Extracellular vesicles in the pathogenesis and treatment of acute lung injury. Mil. Med Res. 9, 61 (2022).","journal-title":"Mil. Med Res."},{"key":"2127_CR272","doi-asserted-by":"publisher","DOI":"10.1186\/cc9978","volume":"15","author":"C Guervilly","year":"2011","unstructured":"Guervilly, C. et al. High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit. Care 15, R31 (2011).","journal-title":"Crit. Care"},{"key":"2127_CR273","doi-asserted-by":"publisher","first-page":"1801188","DOI":"10.1183\/13993003.01188-2018","volume":"54","author":"Y Takei","year":"2019","unstructured":"Takei, Y. et al. Increase in circulating ACE-positive endothelial microparticles during acute lung injury. Eur. Respir. J. 54, 1801188 (2019).","journal-title":"Eur. Respir. J."},{"key":"2127_CR274","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.784028","volume":"12","author":"AS Meidert","year":"2021","unstructured":"Meidert, A. S. et al. Extracellular vesicle Associated miRNAs regulate signaling pathways involved in COVID-19 Pneumonia and the progression to severe acute respiratory Corona Virus-2 Syndrome. Front Immunol. 12, 784028 (2021).","journal-title":"Front Immunol."},{"key":"2127_CR275","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s12276-021-00651-6","volume":"53","author":"G Li","year":"2021","unstructured":"Li, G. et al. Plasma extracellular vesicle delivery of miR-210-3p by targeting ATG7 to promote sepsis-induced acute lung injury by regulating autophagy and activating inflammation. Exp. Mol. Med. 53, 1180\u20131191 (2021).","journal-title":"Exp. Mol. Med."},{"key":"2127_CR276","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1164\/rccm.201410-1765OC","volume":"192","author":"A Monsel","year":"2015","unstructured":"Monsel, A. et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am. J. Respir. Crit. Care Med. 192, 324\u2013336 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR277","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/ALN.0000000000002655","volume":"130","author":"AK Varkouhi","year":"2019","unstructured":"Varkouhi, A. K. et al. Extracellular vesicles from Interferon-gamma-primed human umbilical cord mesenchymal stromal cells reduce escherichia coli-induced acute lung injury in rats. Anesthesiology 130, 778\u2013790 (2019).","journal-title":"Anesthesiology"},{"key":"2127_CR278","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/thoraxjnl-2021-218194","volume":"78","author":"Y Su","year":"2023","unstructured":"Su, Y. et al. Mesenchymal stromal cells-derived extracellular vesicles reprogramme macrophages in ARDS models through the miR-181a-5p-PTEN-pSTAT5-SOCS1 axis. Thorax 78, 617\u2013630 (2023).","journal-title":"Thorax"},{"key":"2127_CR279","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1164\/rccm.201701-0170OC","volume":"196","author":"TJ Morrison","year":"2017","unstructured":"Morrison, T. J. et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am. J. Respir. Crit. Care Med. 196, 1275\u20131286 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR280","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/s41401-021-00625-4","volume":"42","author":"GC Mao","year":"2021","unstructured":"Mao, G. C. et al. BMSC-derived exosomes ameliorate sulfur mustard-induced acute lung injury by regulating the GPRC5A-YAP axis. Acta Pharm. Sin. 42, 2082\u20132093 (2021).","journal-title":"Acta Pharm. Sin."},{"key":"2127_CR281","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9973457","volume":"2021","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. BMSC-derived exosomes ameliorate LPS-induced acute lung injury by miR-384-5p-controlled alveolar macrophage autophagy. Oxid. Med Cell Longev. 2021, 9973457 (2021).","journal-title":"Oxid. Med Cell Longev."},{"key":"2127_CR282","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.7150\/thno.69533","volume":"12","author":"L Xia","year":"2022","unstructured":"Xia, L. et al. AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages. Theranostics 12, 2928\u20132947 (2022).","journal-title":"Theranostics"},{"key":"2127_CR283","doi-asserted-by":"publisher","first-page":"2002978","DOI":"10.1183\/13993003.02978-2020","volume":"58","author":"J Dutra Silva","year":"2021","unstructured":"Dutra Silva, J. et al. Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. Eur. Respir. J. 58, 2002978 (2021).","journal-title":"Eur. Respir. J."},{"key":"2127_CR284","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-018-0197-2","volume":"7","author":"T Shah","year":"2018","unstructured":"Shah, T. et al. Alk5\/Runx1 signaling mediated by extracellular vesicles promotes vascular repair in acute respiratory distress syndrome. Clin. Transl. Med. 7, 19 (2018).","journal-title":"Clin. Transl. Med."},{"key":"2127_CR285","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13287-020-02015-9","volume":"11","author":"Y Mizuta","year":"2020","unstructured":"Mizuta, Y. et al. Exosomes from adipose tissue-derived mesenchymal stem cells ameliorate histone-induced acute lung injury by activating the PI3K\/Akt pathway in endothelial cells. Stem Cell Res. Ther. 11, 508 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"2127_CR286","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/s41418-021-00750-x","volume":"28","author":"Z Feng","year":"2021","unstructured":"Feng, Z. et al. Epithelium- and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response. Cell Death Differ. 28, 2238\u20132256 (2021).","journal-title":"Cell Death Differ."},{"key":"2127_CR287","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2339-3","volume":"23","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury. Crit. Care 23, 44 (2019).","journal-title":"Crit. Care"},{"key":"2127_CR288","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.282","volume":"6","author":"HG Moon","year":"2015","unstructured":"Moon, H. G. et al. Lung epithelial cell-derived extracellular vesicles activate macrophage-mediated inflammatory responses via ROCK1 pathway. Cell Death Dis. 6, e2016 (2015).","journal-title":"Cell Death Dis."},{"key":"2127_CR289","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","volume":"5","author":"JH Beigel","year":"2017","unstructured":"Beigel, J. H. et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir. Med. 5, 500\u2013511 (2017).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR290","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","volume":"7","author":"JH Beigel","year":"2019","unstructured":"Beigel, J. H. et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir. Med. 7, 941\u2013950 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR291","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with Convalescent plasma. JAMA 323, 1582\u20131589 (2020).","journal-title":"JAMA"},{"key":"2127_CR292","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107239","volume":"93","author":"A Allahyari","year":"2021","unstructured":"Allahyari, A. et al. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome. Int Immunopharmacol. 93, 107239 (2021).","journal-title":"Int Immunopharmacol."},{"key":"2127_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28064-7","volume":"13","author":"Y Ray","year":"2022","unstructured":"Ray, Y. et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat. Commun. 13, 383 (2022).","journal-title":"Nat. Commun."},{"key":"2127_CR294","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa102","volume":"7","author":"W Cao","year":"2020","unstructured":"Cao, W. et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus disease 2019. Open Forum Infect. Dis. 7, ofaa102 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"2127_CR295","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1192","volume":"9","author":"Z Shao","year":"2020","unstructured":"Shao, Z. et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin. Transl. Immunol. 9, e1192 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"2127_CR296","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.03.044","volume":"81","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J. Infect. 81, 318\u2013356 (2020).","journal-title":"J. Infect."},{"key":"2127_CR297","doi-asserted-by":"publisher","first-page":"627844","DOI":"10.3389\/fimmu.2021.627844","volume":"12","author":"W Cao","year":"2021","unstructured":"Cao, W. et al. High-dose Intravenous Immunoglobulin in severe coronavirus disease 2019: A Multicenter Retrospective Study in China. Front Immunol. 12, 627844 (2021).","journal-title":"Front Immunol."},{"key":"2127_CR298","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-2600(21)00440-9","volume":"10","author":"A Mazeraud","year":"2022","unstructured":"Mazeraud, A. et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 10, 158\u2013166 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR299","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMe048101","volume":"350","author":"MR Green","year":"2004","unstructured":"Green, M. R. Targeting targeted therapy. N. Engl. J. Med. 350, 2191\u20132193 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2127_CR300","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas, A., Teicher, B. A. & Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 17, e254\u2013e262 (2016).","journal-title":"Lancet Oncol."},{"key":"2127_CR301","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","volume":"181","author":"Z Zhao","year":"2020","unstructured":"Zhao, Z., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151\u2013167 (2020).","journal-title":"Cell"},{"key":"2127_CR302","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","volume":"15","author":"GAR Goncalves","year":"2017","unstructured":"Goncalves, G. A. R. & Paiva, R. M. A. Gene therapy: advances, challenges and perspectives. Einstein 15, 369\u2013375 (2017).","journal-title":"Einstein"},{"key":"2127_CR303","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.3390\/ijms23168875","volume":"23","author":"V Barresi","year":"2022","unstructured":"Barresi, V., Musmeci, C., Rinaldi, A. & Condorelli, D. F. Transcript-targeted therapy based on RNA Interference and Antisense Oligonucleotides: Current applications and novel molecular targets. Int. J. Mol. Sci. 23, 8875 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2127_CR304","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/MCC.0000000000000571","volume":"25","author":"P Sinha","year":"2019","unstructured":"Sinha, P. & Calfee, C. S. Phenotypes in acute respiratory distress syndrome: moving towards precision medicine. Curr. Opin. Crit. Care 25, 12\u201320 (2019).","journal-title":"Curr. Opin. Crit. Care"},{"key":"2127_CR305","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","volume":"398","author":"NJ Meyer","year":"2021","unstructured":"Meyer, N. J., Gattinoni, L. & Calfee, C. S. Acute respiratory distress syndrome. Lancet 398, 622\u2013637 (2021).","journal-title":"Lancet"},{"key":"2127_CR306","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.pupt.2011.03.001","volume":"24","author":"N Aikawa","year":"2011","unstructured":"Aikawa, N. et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm. Pharm. Ther. 24, 549\u2013554 (2011).","journal-title":"Pulm. Pharm. Ther."},{"key":"2127_CR307","doi-asserted-by":"publisher","first-page":"11910","DOI":"10.21037\/apm-21-3164","volume":"10","author":"X Gao","year":"2021","unstructured":"Gao, X. et al. Efficacy, safety, and pharmacoeconomics of sivelestat sodium in the treatment of septic acute respiratory distress syndrome: a retrospective cohort study. Ann. Palliat. Med. 10, 11910\u201311917 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"2127_CR308","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12890-017-0498-z","volume":"17","author":"S Pu","year":"2017","unstructured":"Pu, S. et al. Effect of sivelestat sodium in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. BMC Pulm. Med. 17, 148 (2017).","journal-title":"BMC Pulm. Med."},{"key":"2127_CR309","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cytogfr.2020.03.002","volume":"55","author":"N Zhang","year":"2020","unstructured":"Zhang, N., Wang, Z. & Zhao, Y. Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases. Cytokine Growth Factor Rev. 55, 80\u201385 (2020).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2127_CR310","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/thoraxjnl-2017-210305","volume":"73","author":"A Proudfoot","year":"2018","unstructured":"Proudfoot, A. et al. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax 73, 723\u2013730 (2018).","journal-title":"Thorax"},{"key":"2127_CR311","doi-asserted-by":"publisher","first-page":"14932","DOI":"10.1074\/jbc.M110.182170","volume":"286","author":"H Wu","year":"2011","unstructured":"Wu, H. et al. Keratinocyte growth factor augments pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages. J. Biol. Chem. 286, 14932\u201314940 (2011).","journal-title":"J. Biol. Chem."},{"key":"2127_CR312","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/CCM.0b013e31822d7bf0","volume":"40","author":"R Paine 3rd","year":"2012","unstructured":"Paine, R. 3rd et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit. Care Med. 40, 90\u201397 (2012).","journal-title":"Crit. Care Med."},{"key":"2127_CR313","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1164\/rccm.2009005","volume":"166","author":"JJ Presneill","year":"2002","unstructured":"Presneill, J. J. et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166, 138\u2013143 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR314","doi-asserted-by":"publisher","DOI":"10.1186\/cc12786","volume":"17","author":"IK Kim","year":"2013","unstructured":"Kim, I. K. et al. Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Crit. Care 17, R114 (2013).","journal-title":"Crit. Care"},{"key":"2127_CR315","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1183\/09031936.00054407","volume":"32","author":"MJ Overbeek","year":"2008","unstructured":"Overbeek, M. J. et al. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur. Respir. J. 32, 232\u2013235 (2008).","journal-title":"Eur. Respir. J."},{"key":"2127_CR316","doi-asserted-by":"publisher","first-page":"e691","DOI":"10.1200\/JCO.2011.35.6733","volume":"29","author":"F Carnevale-Schianca","year":"2011","unstructured":"Carnevale-Schianca, F. et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin\u2019s lymphoma: hope for severe chemotherapy-induced toxicity? J. Clin. Oncol. 29, e691\u2013e693 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2127_CR317","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201301-0136LE","volume":"188","author":"J Aman","year":"2013","unstructured":"Aman, J. et al. Reversal of vascular leak with imatinib. Am. J. Respir. Crit. Care Med 188, 1171\u20131173 (2013).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR318","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1874467210801010068","volume":"1","author":"SC Tauber","year":"2008","unstructured":"Tauber, S. C. & Nau, R. Immunomodulatory properties of antibiotics. Curr. Mol. Pharm. 1, 68\u201379 (2008).","journal-title":"Curr. Mol. Pharm."},{"key":"2127_CR319","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1128\/AAC.05798-11","volume":"56","author":"A Spyridaki","year":"2012","unstructured":"Spyridaki, A. et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob. Agents Chemother. 56, 3819\u20133825 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2127_CR320","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2213-2600(23)00412-5","volume":"12","author":"EJ Giamarellos-Bourboulis","year":"2024","unstructured":"Giamarellos-Bourboulis, E. J. et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 12, 294\u2013304 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR321","doi-asserted-by":"publisher","first-page":"210093","DOI":"10.1183\/16000617.0093-2021","volume":"30","author":"A Sauer","year":"2021","unstructured":"Sauer, A., Peukert, K., Putensen, C. & Bode, C. Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment. Eur. Respir. Rev. 30, 210093 (2021).","journal-title":"Eur. Respir. Rev."},{"key":"2127_CR322","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1164\/rccm.201310-1892OC","volume":"189","author":"M Shyamsundar","year":"2014","unstructured":"Shyamsundar, M. et al. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am. J. Respir. Crit. Care Med. 189, 1520\u20131529 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR323","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S2213-2600(17)30171-6","volume":"5","author":"DF McAuley","year":"2017","unstructured":"McAuley, D. F. et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir. Med. 5, 484\u2013491 (2017).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR324","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1851-6","volume":"21","author":"B Gutbier","year":"2017","unstructured":"Gutbier, B. et al. Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal pneumonia. Crit. Care 21, 274 (2017).","journal-title":"Crit. Care"},{"key":"2127_CR325","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bja.2018.05.049","volume":"121","author":"NAM Dekker","year":"2018","unstructured":"Dekker, N. A. M. et al. Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats. Br. J. Anaesth. 121, 1041\u20131051 (2018).","journal-title":"Br. J. Anaesth."},{"key":"2127_CR326","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19560-3","volume":"12","author":"A Lask","year":"2022","unstructured":"Lask, A. et al. Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice. Sci. Rep. 12, 15531 (2022).","journal-title":"Sci. Rep."},{"key":"2127_CR327","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/TCRM.S313003","volume":"17","author":"HP Li","year":"2021","unstructured":"Li, H. P. et al. Therapeutic agents rounding up the immunopathology of COVID-19. Ther. Clin. Risk Manag. 17, 657\u2013668 (2021).","journal-title":"Ther. Clin. Risk Manag."},{"key":"2127_CR328","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/bs.vh.2016.04.003","volume":"102","author":"R King","year":"2016","unstructured":"King, R. & Tuthill, C. Immune modulation with Thymosin Alpha 1 treatment. Vitam. Horm. 102, 151\u2013178 (2016).","journal-title":"Vitam. Horm."},{"key":"2127_CR329","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/fmb-2016-0125","volume":"12","author":"C Matteucci","year":"2017","unstructured":"Matteucci, C. et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiol. 12, 141\u2013155 (2017).","journal-title":"Future Microbiol."},{"key":"2127_CR330","doi-asserted-by":"publisher","first-page":"106873","DOI":"10.1016\/j.intimp.2020.106873","volume":"88","author":"M Wu","year":"2020","unstructured":"Wu, M. et al. Thymosin alpha1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Int. Immunopharmacol. 88, 106873 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR331","doi-asserted-by":"publisher","first-page":"107143","DOI":"10.1016\/j.intimp.2020.107143","volume":"90","author":"Q Sun","year":"2021","unstructured":"Sun, Q. et al. The effect of thymosin alpha1 on mortality of critical COVID-19 patients: A multicenter retrospective study. Int. Immunopharmacol. 90, 107143 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR332","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","volume":"20","author":"FM Lang","year":"2020","unstructured":"Lang, F. M. et al. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat. Rev. Immunol. 20, 507\u2013514 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2127_CR333","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.mayocp.2020.08.038","volume":"95","author":"Z Temesgen","year":"2020","unstructured":"Temesgen, Z. et al. GM-CSF Neutralization with Lenzilumab in severe COVID-19 Pneumonia: A case-cohort study. Mayo Clin. Proc. 95, 2382\u20132394 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"2127_CR334","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S2665-9913(20)30170-3","volume":"2","author":"G De Luca","year":"2020","unstructured":"De Luca, G. et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2, e465\u2013e473 (2020).","journal-title":"Lancet Rheumatol."},{"key":"2127_CR335","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF02386808","volume":"16","author":"BJ Cremin","year":"1986","unstructured":"Cremin, B. J. A review of the ultrasonic appearances of posterior urethral valve and ureteroceles. Pediatr. Radio. 16, 357\u2013364 (1986).","journal-title":"Pediatr. Radio."},{"key":"2127_CR336","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamainternmed.2020.5503","volume":"181","author":"LL Cheng","year":"2021","unstructured":"Cheng, L. L. et al. Effect of recombinant human granulocyte colony-stimulating factor for patients with Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A randomized clinical trial. JAMA Intern Med. 181, 71\u201378 (2021).","journal-title":"JAMA Intern Med."},{"key":"2127_CR337","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s12026-016-8873-z","volume":"64","author":"G Shrivastava","year":"2016","unstructured":"Shrivastava, G. et al. Inflammasomes and its importance in viral infections. Immunol. Res 64, 1101\u20131117 (2016).","journal-title":"Immunol. Res"},{"key":"2127_CR338","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"M Mertens","year":"2009","unstructured":"Mertens, M. & Singh, J. A. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol. 36, 1118\u20131125 (2009).","journal-title":"J. Rheumatol."},{"key":"2127_CR339","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/iid3.563","volume":"10","author":"AB Kharazmi","year":"2022","unstructured":"Kharazmi, A. B. et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Immun. Inflamm. Dis. 10, 201\u2013208 (2022).","journal-title":"Immun. Inflamm. Dis."},{"key":"2127_CR340","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli, G. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2, e325\u2013e331 (2020).","journal-title":"Lancet Rheumatol."},{"key":"2127_CR341","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","volume":"3","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou, E. et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 3, e690\u2013e697 (2021).","journal-title":"Lancet Rheumatol."},{"key":"2127_CR342","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"2127_CR343","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"T Hirano","year":"2020","unstructured":"Hirano, T. & Murakami, M. COVID-19: A new virus, but a familiar receptor and Cytokine Release Syndrome. Immunity 52, 731\u2013733 (2020).","journal-title":"Immunity"},{"key":"2127_CR344","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02107-21","volume":"66","author":"N Merchante","year":"2022","unstructured":"Merchante, N. et al. Early Use of Sarilumab in patients hospitalized with COVID-19 Pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrob. Agents Chemother. 66, e0210721 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2127_CR345","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","volume":"9","author":"FX Lescure","year":"2021","unstructured":"Lescure, F. X. et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 522\u2013532 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR346","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1182\/bloodadvances.2021005246","volume":"6","author":"S Aiello","year":"2022","unstructured":"Aiello, S. et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv. 6, 866\u2013881 (2022).","journal-title":"Blood Adv."},{"key":"2127_CR347","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar, A. P. J. et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 10, 1137\u20131146 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR348","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92\u201398 (2021).","journal-title":"Nature"},{"key":"2127_CR349","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","volume":"34","author":"F La Rosee","year":"2020","unstructured":"La Rosee, F. et al. The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 34, 1805\u20131815 (2020).","journal-title":"Leukemia"},{"key":"2127_CR350","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41375-021-01374-3","volume":"35","author":"A Neubauer","year":"2021","unstructured":"Neubauer, A. et al. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia 35, 2917\u20132923 (2021).","journal-title":"Leukemia"},{"key":"2127_CR351","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.1073\/pnas.87.23.9188","volume":"87","author":"S Shak","year":"1990","unstructured":"Shak, S. et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl Acad. Sci. USA 87, 9188\u20139192 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2127_CR352","doi-asserted-by":"publisher","first-page":"25","DOI":"10.12703\/r\/9-25","volume":"9","author":"FR DeLeo","year":"2020","unstructured":"DeLeo, F. R. & Allen, L. H. Phagocytosis and neutrophil extracellular traps. Fac. Rev. 9, 25 (2020).","journal-title":"Fac. Rev."},{"key":"2127_CR353","doi-asserted-by":"publisher","first-page":"714833","DOI":"10.3389\/fimmu.2021.714833","volume":"12","author":"ZM Holliday","year":"2021","unstructured":"Holliday, Z. M. et al. Non-randomized trial of Dornase Alfa for acute respiratory distress syndrome secondary to Covid-19. Front Immunol. 12, 714833 (2021).","journal-title":"Front Immunol."},{"key":"2127_CR354","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","volume":"44","author":"LK Ward-Kavanagh","year":"2016","unstructured":"Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R. & Ware, C. F. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 44, 1005\u20131019 (2016).","journal-title":"Immunity"},{"key":"2127_CR355","doi-asserted-by":"publisher","first-page":"e153173","DOI":"10.1172\/JCI153173","volume":"132","author":"DS Perlin","year":"2022","unstructured":"Perlin, D. S. et al. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. J. Clin. Invest. 132, e153173 (2022).","journal-title":"J. Clin. Invest."},{"key":"2127_CR356","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2020.00211","volume":"11","author":"C Zhao","year":"2020","unstructured":"Zhao, C. & Zhao, W. NLRP3 Inflammasome-A Key Player in Antiviral Responses. Front. Immunol. 11, 211 (2020).","journal-title":"Front. Immunol."},{"key":"2127_CR357","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","volume":"64","author":"AG Schwaid","year":"2021","unstructured":"Schwaid, A. G. & Spencer, K. B. Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space. J. Med. Chem. 64, 101\u2013122 (2021).","journal-title":"J. Med. Chem."},{"key":"2127_CR358","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s15010-022-01904-w","volume":"51","author":"I Madurka","year":"2023","unstructured":"Madurka, I. et al. DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function. Infection 51, 641\u2013654 (2023).","journal-title":"Infection"},{"key":"2127_CR359","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1007\/s11033-021-06827-7","volume":"48","author":"A Manayi","year":"2021","unstructured":"Manayi, A. et al. Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19. Mol. Biol. Rep. 48, 8221\u20138225 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"2127_CR360","doi-asserted-by":"publisher","first-page":"178","DOI":"10.14715\/cmb\/2021.67.3.28","volume":"67","author":"Y Yue","year":"2021","unstructured":"Yue, Y., Jin, F. & Yue, X. The effect of Borago officinalis on the signaling pathway of the NLRP3 inflammasome complex, TLR4 and some inflammatory cytokines in type II diabetic patients with acute respiratory distress syndrome. Cell. Mol. Biol. 67, 178\u2013183 (2021).","journal-title":"Cell. Mol. Biol."},{"key":"2127_CR361","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bcpt.13503","volume":"128","author":"A Saeedi-Boroujeni","year":"2021","unstructured":"Saeedi-Boroujeni, A., Mahmoudian-Sani, M. R., Bahadoram, M. & Alghasi, A. COVID-19: A case for inhibiting NLRP3 inflammasome, suppression of inflammation with Curcumin? Basic Clin. Pharm. Toxicol. 128, 37\u201345 (2021).","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"2127_CR362","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/08923973.2022.2073890","volume":"44","author":"X Niu","year":"2022","unstructured":"Niu, X. et al. Tectoridin alleviates lipopolysaccharide-induced inflammation via inhibiting TLR4-NF-kappaB\/NLRP3 signaling in vivo and in vitro. Immunopharmacol. Immunotoxicol. 44, 641\u2013655 (2022).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"2127_CR363","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2147\/DDDT.S247103","volume":"14","author":"Z Gao","year":"2020","unstructured":"Gao, Z. et al. Emodin protects against acute pancreatitis-associated lung injury by inhibiting NLPR3 Inflammasome activation via Nrf2\/HO-1 signaling. Drug Des. Dev. Ther. 14, 1971\u20131982 (2020).","journal-title":"Drug Des. Dev. Ther."},{"key":"2127_CR364","doi-asserted-by":"publisher","first-page":"781003","DOI":"10.3389\/fimmu.2022.781003","volume":"13","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. HSF1 protects Sepsis-induced acute lung injury by inhibiting NLRP3 Inflammasome Activation. Front. Immunol. 13, 781003 (2022).","journal-title":"Front. Immunol."},{"key":"2127_CR365","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jpi.12322","volume":"60","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J. Pineal Res. 60, 405\u2013414 (2016).","journal-title":"J. Pineal Res."},{"key":"2127_CR366","doi-asserted-by":"publisher","first-page":"812164","DOI":"10.3389\/fimmu.2022.812164","volume":"13","author":"J Li","year":"2022","unstructured":"Li, J. et al. A 4-Benzene-Indol derivative alleviates LPS-induced acute lung injury through inhibiting the NLRP3 inflammasome. Front Immunol. 13, 812164 (2022).","journal-title":"Front Immunol."},{"key":"2127_CR367","doi-asserted-by":"publisher","first-page":"175047","DOI":"10.1016\/j.ejphar.2022.175047","volume":"926","author":"G He","year":"2022","unstructured":"He, G. et al. Fudosteine attenuates acute lung injury in septic mice by inhibiting pyroptosis via the TXNIP\/NLRP3\/GSDMD pathway. Eur. J. Pharm. 926, 175047 (2022).","journal-title":"Eur. J. Pharm."},{"key":"2127_CR368","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/SHK.0000000000001927","volume":"57","author":"Q Meng","year":"2022","unstructured":"Meng, Q. et al. Nano-chemically modified Tetracycline-3 (nCMT-3) attenuates acute lung injury via blocking sTREM-1 release and NLRP3 Inflammasome activation. Shock 57, 749\u2013758 (2022).","journal-title":"Shock"},{"key":"2127_CR369","doi-asserted-by":"publisher","first-page":"8457010","DOI":"10.1155\/2022\/8457010","volume":"2022","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Glibenclamide alleviates LPS-induced acute lung injury through NLRP3 Inflammasome signaling pathway. Mediators Inflamm. 2022, 8457010 (2022).","journal-title":"Mediators Inflamm."},{"key":"2127_CR370","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/SHK.0000000000001835","volume":"56","author":"P Pan","year":"2021","unstructured":"Pan, P. et al. FUNDC1 regulates autophagy by inhibiting ROS-NLRP3 signaling to avoid apoptosis in the lung in a Lipopolysaccharide-induced mouse model. Shock 56, 773\u2013781 (2021).","journal-title":"Shock"},{"key":"2127_CR371","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/08923973.2021.1925293","volume":"43","author":"A Saeedi-Boroujeni","year":"2021","unstructured":"Saeedi-Boroujeni, A. et al. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacol. Immunotoxicol. 43, 247\u2013258 (2021).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"2127_CR372","doi-asserted-by":"publisher","first-page":"115954","DOI":"10.1016\/j.bmc.2020.115954","volume":"30","author":"L Wang","year":"2021","unstructured":"Wang, L., Lei, W., Zhang, S. & Yao, L. MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice. Bioorg. Med. Chem. 30, 115954 (2021).","journal-title":"Bioorg. Med. Chem."},{"key":"2127_CR373","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.3892\/mmr.2020.11335","volume":"22","author":"T Ming","year":"2020","unstructured":"Ming, T. et al. Dexmedetomidine alleviates blunt chest trauma and hemorrhagic shock\u2011resuscitation\u2011induced acute lung injury through inhibiting the NLRP3 inflammasome. Mol. Med. Rep. 22, 2507\u20132515 (2020).","journal-title":"Mol. Med. Rep."},{"key":"2127_CR374","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.18632\/aging.202379","volume":"13","author":"SS Wang","year":"2021","unstructured":"Wang, S. S., Yan, C. S. & Luo, J. M. NLRC4 gene silencing-dependent blockade of NOD-like receptor pathway inhibits inflammation, reduces proliferation and increases apoptosis of dendritic cells in mice with septic shock. Aging 13, 1440\u20131457 (2021).","journal-title":"Aging"},{"key":"2127_CR375","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.bbrc.2020.08.109","volume":"533","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. PIM2 deletion alleviates lipopolysaccharide (LPS)-induced respiratory distress syndrome (ARDS) by suppressing NLRP3 inflammasome. Biochem. Biophys. Res. Commun. 533, 1419\u20131426 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2127_CR376","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","volume":"99","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol. Immunol. 99, 134\u2013144 (2018).","journal-title":"Mol. Immunol."},{"key":"2127_CR377","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00011-023-01705-3","volume":"72","author":"F Long","year":"2023","unstructured":"Long, F. et al. RBM3 is associated with acute lung injury in septic mice and patients via the NF-kappaB\/NLRP3 pathway. Inflamm. Res. 72, 731\u2013744 (2023).","journal-title":"Inflamm. Res."},{"key":"2127_CR378","first-page":"457","volume":"23","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Sivelestat sodium attenuates acute lung injury by inhibiting JNK\/NF-kappaB and activating Nrf2\/HO-1 signaling pathways. Biomol. Biomed. 23, 457\u2013470 (2023).","journal-title":"Biomol. Biomed."},{"key":"2127_CR379","doi-asserted-by":"publisher","DOI":"10.1590\/0001-3765202220211327","volume":"94","author":"LR Bernardo","year":"2022","unstructured":"Bernardo, L. R. et al. Milonine attenuates the lipopolysaccharide-induced acute lung injury in mice by modulating the Akt\/NF-kappaB signaling pathways. Acad. Bras. Cienc. 94, e20211327 (2022).","journal-title":"Acad. Bras. Cienc."},{"key":"2127_CR380","doi-asserted-by":"publisher","first-page":"919898","DOI":"10.3389\/fphar.2022.919898","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Allyl methyl trisulfide protected against LPS-induced acute lung injury in mice via inhibition of the NF-kappaB and MAPK pathways. Front. Pharm. 13, 919898 (2022).","journal-title":"Front. Pharm."},{"key":"2127_CR381","doi-asserted-by":"publisher","first-page":"793107","DOI":"10.3389\/fphar.2021.793107","volume":"12","author":"YT Tung","year":"2021","unstructured":"Tung, Y. T. et al. Aspirin attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by suppressing pulmonary inflammation via the NF-kappaB Signaling Pathway. Front Pharm. 12, 793107 (2021).","journal-title":"Front Pharm."},{"key":"2127_CR382","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.2147\/JIR.S335915","volume":"14","author":"F Gong","year":"2021","unstructured":"Gong, F. et al. OLFM4 regulates lung epithelial cell function in sepsis-associated ARDS\/ALI via LDHA-Mediated NF-kappaB Signaling. J. Inflamm. Res. 14, 7035\u20137051 (2021).","journal-title":"J. Inflamm. Res."},{"key":"2127_CR383","doi-asserted-by":"publisher","first-page":"112209","DOI":"10.1016\/j.biopha.2021.112209","volume":"143","author":"H Qian","year":"2021","unstructured":"Qian, H. et al. Andrographolide sulfonate attenuates alveolar hypercoagulation and fibrinolytic inhibition partly via NF-kappaB pathway in LPS-induced acute respiratory distress syndrome in mice. Biomed. Pharmacother. 143, 112209 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"2127_CR384","doi-asserted-by":"publisher","first-page":"153729","DOI":"10.1016\/j.phymed.2021.153729","volume":"92","author":"SK Tirunavalli","year":"2021","unstructured":"Tirunavalli, S. K. et al. Dehydrozingerone ameliorates Lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress via modulating the MAPK\/NF-kappaB pathway. Phytomedicine 92, 153729 (2021).","journal-title":"Phytomedicine"},{"key":"2127_CR385","doi-asserted-by":"publisher","first-page":"174349","DOI":"10.1016\/j.ejphar.2021.174349","volume":"908","author":"G Xu","year":"2021","unstructured":"Xu, G. et al. Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4\/NF-kappaB and JAK2\/STAT3 inhibition. Eur. J. Pharm. 908, 174349 (2021).","journal-title":"Eur. J. Pharm."},{"key":"2127_CR386","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107020","volume":"88","author":"B Liu","year":"2020","unstructured":"Liu, B. et al. Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-kappaB inactivation. Int. Immunopharmacol. 88, 107020 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR387","doi-asserted-by":"publisher","first-page":"731","DOI":"10.21037\/atm.2019.11.126","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Gentiopicroside (GENT) protects against sepsis induced by lipopolysaccharide (LPS) through the NF-kappaB signaling pathway. Ann. Transl. Med. 7, 731 (2019).","journal-title":"Ann. Transl. Med."},{"key":"2127_CR388","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1247-9","volume":"10","author":"V Pooladanda","year":"2019","unstructured":"Pooladanda, V. et al. Nimbolide protects against endotoxin-induced acute respiratory distress syndrome by inhibiting TNF-alpha mediated NF-kappaB and HDAC-3 nuclear translocation. Cell Death Dis. 10, 81 (2019).","journal-title":"Cell Death Dis."},{"key":"2127_CR389","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.bcp.2018.07.025","volume":"155","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. Euphorbia factor L2 alleviates lipopolysaccharide-induced acute lung injury and inflammation in mice through the suppression of NF-kappaB activation. Biochem. Pharm. 155, 444\u2013454 (2018).","journal-title":"Biochem. Pharm."},{"key":"2127_CR390","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10787-022-01133-5","volume":"31","author":"A Jangam","year":"2023","unstructured":"Jangam, A. et al. Anti-inflammatory and antioxidant activities of Gymnema Sylvestre extract rescue acute respiratory distress syndrome in rats via modulating the NF-kappaB\/MAPK pathway. Inflammopharmacology 31, 823\u2013844 (2023).","journal-title":"Inflammopharmacology"},{"key":"2127_CR391","doi-asserted-by":"publisher","first-page":"4934592","DOI":"10.1155\/2018\/4934592","volume":"2018","author":"Y Jin","year":"2018","unstructured":"Jin, Y. et al. Osthole protects against acute lung injury by suppressing NF-kappaB-dependent inflammation. Mediators Inflamm. 2018, 4934592 (2018).","journal-title":"Mediators Inflamm."},{"key":"2127_CR392","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1631\/jzus.B2000583","volume":"22","author":"X Kan","year":"2021","unstructured":"Kan, X. et al. Effect of Palrnatine on lipopolysaccharide-induced acute lung injury by inhibiting activation of the Akt\/NF\u200d-kappaB pathway. J. Zhejiang Univ. Sci. B 22, 929\u2013940 (2021).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"2127_CR393","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1002\/ptr.7315","volume":"35","author":"OA Olajide","year":"2021","unstructured":"Olajide, O. A. et al. Garcinia kola and garcinoic acid suppress SARS-CoV-2 spike glycoprotein S1-induced hyper-inflammation in human PBMCs through inhibition of NF-kappaB activation. Phytother. Res. 35, 6963\u20136973 (2021).","journal-title":"Phytother. Res."},{"key":"2127_CR394","doi-asserted-by":"publisher","first-page":"105831","DOI":"10.1016\/j.micpath.2022.105831","volume":"173","author":"F Olimpio","year":"2022","unstructured":"Olimpio, F., Carvalho, J., Kaminsky, V. & Aimbire, F. Lacticaseibacillus rhamnosus attenuates acute lung inflammation in a murine model of acute respiratory distress syndrome: Relevance to cytokines associated to STAT4\/T-bet and STAT3\/ROR\u0263t. Micro. Pathog. 173, 105831 (2022).","journal-title":"Micro. Pathog."},{"key":"2127_CR395","doi-asserted-by":"publisher","first-page":"9646","DOI":"10.1111\/jcmm.15481","volume":"24","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. MCTR1 enhances the resolution of lipopolysaccharide-induced lung injury through STAT6-mediated resident M2 alveolar macrophage polarization in mice. J. Cell Mol. Med. 24, 9646\u20139657 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"2127_CR396","doi-asserted-by":"publisher","first-page":"L882","DOI":"10.1152\/ajplung.00418.2017","volume":"314","author":"H Jin","year":"2018","unstructured":"Jin, H. et al. Surfactant protein C dampens inflammation by decreasing JAK\/STAT activation during lung repair. Am. J. Physiol. Lung Cell Mol. Physiol. 314, L882\u2013L892 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR397","doi-asserted-by":"publisher","first-page":"L868","DOI":"10.1152\/ajplung.00281.2016","volume":"311","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 311, L868\u2013L880 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR398","doi-asserted-by":"publisher","first-page":"e1006955","DOI":"10.1371\/journal.ppat.1006955","volume":"14","author":"H Namkoong","year":"2018","unstructured":"Namkoong, H. et al. Clarithromycin expands CD11b+Gr-1+ cells via the STAT3\/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. PLoS Pathog. 14, e1006955 (2018).","journal-title":"PLoS Pathog."},{"key":"2127_CR399","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pupt.2017.05.002","volume":"45","author":"C Li","year":"2017","unstructured":"Li, C. et al. Losartan, a selective antagonist of AT1 receptor, attenuates seawater inhalation induced lung injury via modulating JAK2\/STATs and apoptosis in rat. Pulm. Pharm. Ther. 45, 69\u201379 (2017).","journal-title":"Pulm. Pharm. Ther."},{"key":"2127_CR400","doi-asserted-by":"publisher","first-page":"899","DOI":"10.14336\/AD.2021.1023","volume":"13","author":"Y Cui","year":"2022","unstructured":"Cui, Y. et al. MiR-29a-3p improves acute lung injury by reducing alveolar epithelial cell PANoptosis. Aging Dis. 13, 899\u2013909 (2022).","journal-title":"Aging Dis."},{"key":"2127_CR401","doi-asserted-by":"publisher","first-page":"11732","DOI":"10.1080\/21655979.2022.2071020","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang, Z. et al. MicroRNA-155-5p modulates the progression of acute respiratory distress syndrome by targeting interleukin receptors. Bioengineered 13, 11732\u201311741 (2022).","journal-title":"Bioengineered"},{"key":"2127_CR402","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3892\/etm.2021.10713","volume":"22","author":"J Li","year":"2021","unstructured":"Li, J., Zeng, X. & Wang, W. miR-122-5p downregulation attenuates lipopolysaccharide-induced acute lung injury by targeting IL1. Rn. Exp. Ther. Med. 22, 1278 (2021).","journal-title":"Rn. Exp. Ther. Med."},{"key":"2127_CR403","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1165\/rcmb.2020-0112OC","volume":"64","author":"B He","year":"2021","unstructured":"He, B. et al. MicroRNA-574-5p attenuates acute respiratory distress syndrome by targeting HMGB1. Am. J. Respir. Cell Mol. Biol. 64, 196\u2013207 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2127_CR404","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1753425920971347","volume":"27","author":"P Li","year":"2021","unstructured":"Li, P., Yao, Y., Ma, Y. & Chen, Y. MiR-30a-5p ameliorates LPS-induced inflammatory injury in human A549 cells and mice via targeting RUNX2. Innate Immun. 27, 41\u201349 (2021).","journal-title":"Innate Immun."},{"key":"2127_CR405","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5603\/FHC.a2019.0019","volume":"57","author":"L Meng","year":"2019","unstructured":"Meng, L., Cao, H., Wan, C. & Jiang, L. MiR-539-5p alleviates sepsis-induced acute lung injury by targeting ROCK1. Folia Histochem. Cytobiol. 57, 168\u2013178 (2019).","journal-title":"Folia Histochem. Cytobiol."},{"key":"2127_CR406","doi-asserted-by":"publisher","first-page":"106197","DOI":"10.1016\/j.intimp.2020.106197","volume":"80","author":"X Xi","year":"2020","unstructured":"Xi, X., Yao, Y., Liu, N. & Li, P. MiR-297 alleviates LPS-induced A549 cell and mice lung injury via targeting cyclin dependent kinase 8. Int. Immunopharmacol. 80, 106197 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR407","doi-asserted-by":"publisher","first-page":"L426","DOI":"10.1152\/ajplung.00195.2015","volume":"310","author":"Z Yuan","year":"2016","unstructured":"Yuan, Z. et al. TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L426\u2013L438 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR408","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00011-019-01295-z","volume":"69","author":"Q You","year":"2020","unstructured":"You, Q. et al. MiR-802 alleviates lipopolysaccharide-induced acute lung injury by targeting Peli2. Inflamm. Res 69, 75\u201385 (2020).","journal-title":"Inflamm. Res"},{"key":"2127_CR409","doi-asserted-by":"publisher","first-page":"BSR20192132","DOI":"10.1042\/BSR20192132","volume":"40","author":"Y Liang","year":"2020","unstructured":"Liang, Y. et al. MiR-124-3p helps to protect against acute respiratory distress syndrome by targeting p65. Biosci Rep. 40, BSR20192132 (2020).","journal-title":"Biosci Rep."},{"key":"2127_CR410","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/genes11090966","volume":"11","author":"MJ Khan","year":"2020","unstructured":"Khan, M. J. et al. Inhibition of miRNA-34a promotes M2 macrophage polarization and improves LPS-induced lung injury by targeting Klf4. Genes 11, 966 (2020).","journal-title":"Genes"},{"key":"2127_CR411","doi-asserted-by":"publisher","first-page":"102498","DOI":"10.1016\/j.nano.2021.102498","volume":"40","author":"SM Niemiec","year":"2022","unstructured":"Niemiec, S. M. et al. Lung function improves after delayed treatment with CNP-miR146a following acute lung injury. Nanomedicine 40, 102498 (2022).","journal-title":"Nanomedicine"},{"key":"2127_CR412","first-page":"2405943","volume":"2022","author":"YM Wang","year":"2022","unstructured":"Wang, Y. M. et al. Mucin 1 inhibits ferroptosis and sensitizes Vitamin E to alleviate sepsis-induced acute lung injury through GSK3beta\/Keap1-Nrf2-GPX4 pathway. Oxid. Med Cell Longev. 2022, 2405943 (2022).","journal-title":"Oxid. Med Cell Longev."},{"key":"2127_CR413","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s00018-022-04248-8","volume":"79","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. AUF1 protects against ferroptosis to alleviate sepsis-induced acute lung injury by regulating NRF2 and ATF3. Cell Mol. Life Sci. 79, 228 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"2127_CR414","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12026-021-09240-1","volume":"70","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Zhao, Y. & Yang, X. Azilsartan attenuates lipopolysaccharide-induced acute lung injury via the Nrf2\/HO-1 signaling pathway. Immunol. Res. 70, 97\u2013105 (2022).","journal-title":"Immunol. Res."},{"key":"2127_CR415","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/SHK.0000000000001859","volume":"57","author":"W Liang","year":"2022","unstructured":"Liang, W. et al. Sulforaphane-dependent up-regulation of NRF2 activity alleviates both systemic inflammatory response and lung injury after Hemorrhagic Shock\/Resuscitation in Mice. Shock 57, 221\u2013229 (2022).","journal-title":"Shock"},{"key":"2127_CR416","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/21655979.2021.2021065","volume":"13","author":"W Yang","year":"2022","unstructured":"Yang, W. et al. Ramelteon protects against human pulmonary microvascular endothelial cell injury induced by lipopolysaccharide (LPS) via activating nuclear factor erythroid 2-related factor 2 (Nrf2)\/heme oxygenase-1 (HO-1) pathway. Bioengineered 13, 1518\u20131529 (2022).","journal-title":"Bioengineered"},{"key":"2127_CR417","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/ddr.21839","volume":"82","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Dasatinib protects against acute respiratory distress syndrome via Nrf2-regulated M2 macrophages polarization. Drug Dev. Res. 82, 1247\u20131257 (2021).","journal-title":"Drug Dev. Res."},{"key":"2127_CR418","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.freeradbiomed.2021.01.045","volume":"165","author":"L Hou","year":"2021","unstructured":"Hou, L. et al. MitoQ alleviates LPS-mediated acute lung injury through regulating Nrf2\/Drp1 pathway. Free Radic. Biol. Med. 165, 219\u2013228 (2021).","journal-title":"Free Radic. Biol. Med."},{"key":"2127_CR419","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.intimp.2019.04.008","volume":"72","author":"G Feng","year":"2019","unstructured":"Feng, G. et al. EphA2 antagonism alleviates LPS-induced acute lung injury via Nrf2\/HO-1, TLR4\/MyD88 and RhoA\/ROCK pathways. Int. Immunopharmacol. 72, 176\u2013185 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR420","doi-asserted-by":"publisher","first-page":"103667","DOI":"10.1016\/j.resp.2021.103667","volume":"289","author":"P Yao","year":"2021","unstructured":"Yao, P., Zhang, Z. & Cao, J. Isorhapontigenin alleviates lipopolysaccharide-induced acute lung injury via modulating Nrf2 signaling. Respir. Physiol. Neurobiol. 289, 103667 (2021).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"2127_CR421","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.113795","volume":"270","author":"W Lee","year":"2021","unstructured":"Lee, W. et al. Botanical formulation, TADIOS, alleviates lipopolysaccharide (LPS)-Induced acute lung injury in mice via modulation of the Nrf2-HO-1 signaling pathway. J. Ethnopharmacol. 270, 113795 (2021).","journal-title":"J. Ethnopharmacol."},{"key":"2127_CR422","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02745-1","volume":"19","author":"J Li","year":"2021","unstructured":"Li, J. et al. Panaxydol attenuates ferroptosis against LPS-induced acute lung injury in mice by Keap1-Nrf2\/HO-1 pathway. J. Transl. Med. 19, 96 (2021).","journal-title":"J. Transl. Med."},{"key":"2127_CR423","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108773","volume":"108","author":"A Patangrao Renushe","year":"2022","unstructured":"Patangrao Renushe, A. et al. Vincamine, an active constituent of Vinca rosea ameliorates experimentally induced acute lung injury in Swiss albino mice through modulation of Nrf-2\/NF-kappaB signaling cascade. Int Immunopharmacol. 108, 108773 (2022).","journal-title":"Int Immunopharmacol."},{"key":"2127_CR424","doi-asserted-by":"publisher","first-page":"113385","DOI":"10.1016\/j.jep.2020.113385","volume":"265","author":"YX Deng","year":"2021","unstructured":"Deng, Y. X. et al. Active ingredients targeting Nrf2 in the Mongolian medicine Qiwei Putao powder: Systematic pharmacological prediction and validation for chronic obstructive pulmonary disease treatment. J. Ethnopharmacol. 265, 113385 (2021).","journal-title":"J. Ethnopharmacol."},{"key":"2127_CR425","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ja.2017.74","volume":"70","author":"HT Quach","year":"2017","unstructured":"Quach, H. T. et al. Allantopyrone A interferes with multiple components of the TNF receptor 1 complex and blocks RIP1 modifications in the TNF-alpha-induced signaling pathway. J. Antibiot. 70, 929\u2013936 (2017).","journal-title":"J. Antibiot."},{"key":"2127_CR426","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2017.00128","volume":"8","author":"MR Wilson","year":"2017","unstructured":"Wilson, M. R. et al. Inhibition of TNF Receptor p55 By a domain antibody attenuates the initial phase of acid-induced lung injury in mice. Front Immunol. 8, 128 (2017).","journal-title":"Front Immunol."},{"key":"2127_CR427","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00408-014-9628-z","volume":"192","author":"S Patel","year":"2014","unstructured":"Patel, S. et al. HJP272, a novel endothelin receptor antagonist, attenuates lipopolysaccharide-induced acute lung injury in hamsters. Lung 192, 803\u2013810 (2014).","journal-title":"Lung"},{"key":"2127_CR428","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/SHK.0b013e3181507234","volume":"29","author":"G Malleo","year":"2008","unstructured":"Malleo, G. et al. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Shock 29, 560\u2013571 (2008).","journal-title":"Shock"},{"key":"2127_CR429","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10787-022-01117-5","volume":"31","author":"ZT Zhang","year":"2023","unstructured":"Zhang, Z. T. et al. Dexmedetomidine alleviates acute lung injury by promoting Tregs differentiation via activation of AMPK\/SIRT1 pathway. Inflammopharmacology 31, 423\u2013438 (2023).","journal-title":"Inflammopharmacology"},{"key":"2127_CR430","doi-asserted-by":"publisher","first-page":"625627","DOI":"10.3389\/fimmu.2021.625627","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Melatonin attenuates sepsis-induced small-intestine injury by upregulating SIRT3-mediated oxidative-stress inhibition, mitochondrial protection, and autophagy induction. Front Immunol. 12, 625627 (2021).","journal-title":"Front Immunol."},{"key":"2127_CR431","doi-asserted-by":"publisher","first-page":"105658","DOI":"10.1016\/j.intimp.2019.05.043","volume":"74","author":"Q Gong","year":"2019","unstructured":"Gong, Q. et al. DL-3-n-butylphthalide attenuates lipopolysaccharide-induced acute lung injury via SIRT1-dependent and -independent regulation of Nrf2. Int. Immunopharmacol. 74, 105658 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR432","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.transproceed.2020.01.133","volume":"52","author":"D Yu-Wung Yeh","year":"2020","unstructured":"Yu-Wung Yeh, D. & Wang, J. J. Curcumin attenuates hemorrhagic shock and blood replenish resuscitation-induced impairment of pulmonary barrier function by increasing SIRT1 and reducing Malondialdehyde and TNF-alpha contents and neutrophil infiltration in lung in a dose-dependent fashion. Transpl. Proc. 52, 1875\u20131879 (2020).","journal-title":"Transpl. Proc."},{"key":"2127_CR433","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/jphp.13087","volume":"71","author":"M Quan","year":"2019","unstructured":"Quan, M. et al. Tanshinone IIA protects against lipopolysaccharide-induced lung injury through targeting Sirt1. J. Pharm. Pharm. 71, 1142\u20131151 (2019).","journal-title":"J. Pharm. Pharm."},{"key":"2127_CR434","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1566524017666170421151940","volume":"17","author":"X Yang","year":"2017","unstructured":"Yang, X. et al. Hydroxytyrosol attenuates LPS-induced acute lung injury in mice by regulating autophagy and Sirtuin Expression. Curr. Mol. Med. 17, 149\u2013159 (2017).","journal-title":"Curr. Mol. Med."},{"key":"2127_CR435","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/SHK.0000000000000225","volume":"42","author":"W Xu","year":"2014","unstructured":"Xu, W. et al. Novel role of resveratrol: suppression of high-mobility group protein box 1 nucleocytoplasmic translocation by the upregulation of sirtuin 1 in sepsis-induced liver injury. Shock 42, 440\u2013447 (2014).","journal-title":"Shock"},{"key":"2127_CR436","doi-asserted-by":"publisher","first-page":"121334","DOI":"10.1016\/j.lfs.2022.121334","volume":"321","author":"YF Tsai","year":"2023","unstructured":"Tsai, Y. F. et al. Carnosic acid inhibits reactive oxygen species-dependent neutrophil extracellular trap formation and ameliorates acute respiratory distress syndrome. Life Sci. 321, 121334 (2023).","journal-title":"Life Sci."},{"key":"2127_CR437","doi-asserted-by":"publisher","first-page":"1030991","DOI":"10.3389\/fphar.2022.1030991","volume":"13","author":"S Baron","year":"2022","unstructured":"Baron, S. et al. Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro. Front. Pharm. 13, 1030991 (2022).","journal-title":"Front. Pharm."},{"key":"2127_CR438","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s10753-022-01666-5","volume":"45","author":"WH Pan","year":"2022","unstructured":"Pan, W. H. et al. The Effect and Mechanism of Lipoxin A4 on Neutrophil Function in LPS-Induced Lung Injury. Inflammation 45, 1950\u20131967 (2022).","journal-title":"Inflammation"},{"key":"2127_CR439","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/nu11040831","volume":"11","author":"GP de Oliveira","year":"2019","unstructured":"de Oliveira, G. P. et al. Glutamine therapy reduces inflammation and extracellular trap release in experimental acute respiratory distress syndrome of pulmonary origin. Nutrients 11, 831 (2019).","journal-title":"Nutrients"},{"key":"2127_CR440","doi-asserted-by":"publisher","first-page":"L654","DOI":"10.1152\/ajplung.00501.2016","volume":"314","author":"YW Chang","year":"2018","unstructured":"Chang, Y. W. et al. beta-Nitrostyrene derivatives attenuate LPS-mediated acute lung injury via the inhibition of neutrophil-platelet interactions and NET release. Am. J. Physiol. Lung Cell Mol. Physiol. 314, L654\u2013L669 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2127_CR441","doi-asserted-by":"publisher","first-page":"1054176","DOI":"10.3389\/fphar.2022.1054176","volume":"13","author":"T Shang","year":"2022","unstructured":"Shang, T. et al. Xuebijing injection inhibited neutrophil extracellular traps to reverse lung injury in sepsis mice via reducing Gasdermin D. Front. Pharm. 13, 1054176 (2022).","journal-title":"Front. Pharm."},{"key":"2127_CR442","volume":"2022","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. Salvianolic Acid A protects against Lipopolysaccharide-induced acute lung injury by inhibiting Neutrophil NETosis. Oxid. Med. Cell Longev. 2022, 7411824 (2022).","journal-title":"Oxid. Med. Cell Longev."},{"key":"2127_CR443","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1111\/bph.15597","volume":"178","author":"TI Kao","year":"2021","unstructured":"Kao, T. I. et al. Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity. Br. J. Pharm. 178, 4069\u20134084 (2021).","journal-title":"Br. J. Pharm."},{"key":"2127_CR444","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153635","volume":"90","author":"C Yang","year":"2021","unstructured":"Yang, C. et al. Re-Du-Ning injection ameliorates LPS-induced lung injury through inhibiting neutrophil extracellular traps formation. Phytomedicine 90, 153635 (2021).","journal-title":"Phytomedicine"},{"key":"2127_CR445","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107699","volume":"98","author":"Z Gu","year":"2021","unstructured":"Gu, Z. et al. Polydatin alleviates severe traumatic brain injury induced acute lung injury by inhibiting S100B mediated NETs formation. Int. Immunopharmacol. 98, 107699 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"2127_CR446","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1164\/rccm.202108-1908ST","volume":"204","author":"FA Shah","year":"2021","unstructured":"Shah, F. A. et al. A research agenda for precision medicine in sepsis and acute respiratory distress syndrome: An Official American Thoracic Society Research Statement. Am. J. Respir. Crit. Care Med. 204, 891\u2013901 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR447","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2213-2600(19)30352-2","volume":"8","author":"L Ball","year":"2020","unstructured":"Ball, L., Silva, P. L., Rocco, P. R. M. & Pelosi, P. A critical approach to personalised medicine in ARDS. Lancet Respir. Med. 8, 218\u2013219 (2020).","journal-title":"Lancet Respir. Med"},{"key":"2127_CR448","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1164\/rccm.202109-2213ED","volume":"204","author":"K Reddy","year":"2021","unstructured":"Reddy, K., Hardin, C. C. & McAuley, D. F. COVID-19-related Acute Respiratory Distress Syndrome Subphenotypes and differential response to Corticosteroids: Time for more precision? Am. J. Respir. Crit. Care Med. 204, 1241\u20131243 (2021).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2127_CR449","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30089-X","volume":"7","author":"H Zhang","year":"2019","unstructured":"Zhang, H., Li, Y. & Slutsky, A. S. Precision medicine for cell therapy in acute respiratory distress syndrome. Lancet Respir. Med. 7, e13 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR450","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S2213-2600(19)30138-9","volume":"7","author":"JM Constantin","year":"2019","unstructured":"Constantin, J. M. et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir. Med. 7, 870\u2013880 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2127_CR451","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1164\/rccm.202009-3536OC","volume":"203","author":"EC Goligher","year":"2021","unstructured":"Goligher, E. C. et al. Effect of Lowering Vt on mortality in acute respiratory distress syndrome varies with respiratory system elastance. Am. J. Respir. Crit. Care Med. 203, 1378\u20131385 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR452","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1164\/rccm.202009-3539OC","volume":"204","author":"T Sarge","year":"2021","unstructured":"Sarge, T. et al. Effect of Esophageal pressure-guided positive end-expiratory pressure on survival from acute respiratory distress syndrome: a risk-based and mechanistic reanalysis of the EPVent-2 Trial. Am. J. Respir. Crit. Care Med. 204, 1153\u20131163 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR453","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijid.2020.10.059","volume":"102","author":"D Xiao","year":"2021","unstructured":"Xiao, D. et al. Could SARS-CoV-2-induced lung injury be attenuated by vitamin D? Int. J. Infect. Dis. 102, 196\u2013202 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"2127_CR454","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.11825","volume":"322","author":"AA Fowler","year":"2019","unstructured":"Fowler, A. A. et al. Effect of Vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: The CITRIS-ALI randomized clinical trial. JAMA 322, 1261\u20131270 (2019).","journal-title":"JAMA"},{"key":"2127_CR455","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.ajpath.2021.05.015","volume":"191","author":"H Okamoto","year":"2021","unstructured":"Okamoto, H. et al. Recombinant Antithrombin attenuates acute respiratory distress syndrome in experimental Endotoxemia. Am. J. Pathol. 191, 1526\u20131536 (2021).","journal-title":"Am. J. Pathol."},{"key":"2127_CR456","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1111\/bph.15153","volume":"177","author":"K Suzuki","year":"2020","unstructured":"Suzuki, K. et al. Recombinant thrombomodulin protects against LPS-induced acute respiratory distress syndrome via preservation of pulmonary endothelial glycocalyx. Br. J. Pharm. 177, 4021\u20134033 (2020).","journal-title":"Br. J. Pharm."},{"key":"2127_CR457","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101534","volume":"11","author":"ER Brannon","year":"2022","unstructured":"Brannon, E. R. et al. Polysalicylic acid polymer microparticle decoys therapeutically treat acute respiratory distress syndrome. Adv. Health. Mater. 11, e2101534 (2022).","journal-title":"Adv. Health. Mater."},{"key":"2127_CR458","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00011-019-01314-z","volume":"69","author":"D Zhang","year":"2020","unstructured":"Zhang, D. et al. Crocin alleviates lipopolysaccharide-induced acute respiratory distress syndrome by protecting against glycocalyx damage and suppressing inflammatory signaling pathways. Inflamm. Res. 69, 267\u2013278 (2020).","journal-title":"Inflamm. Res"},{"key":"2127_CR459","doi-asserted-by":"publisher","first-page":"113459","DOI":"10.1016\/j.biopha.2022.113459","volume":"153","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed. Pharmacother. 153, 113459 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"2127_CR460","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","volume":"54","author":"H Xian","year":"2021","unstructured":"Xian, H. et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity 54, 1463\u20131477, e1411 (2021).","journal-title":"Immunity"},{"key":"2127_CR461","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202203432","volume":"18","author":"K Wang","year":"2022","unstructured":"Wang, K. et al. Fluorous-tagged peptide nanoparticles ameliorate acute lung injury via lysosomal stabilization and inflammation inhibition in pulmonary macrophages. Small 18, e2203432 (2022).","journal-title":"Small"},{"key":"2127_CR462","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2021.152177","volume":"809","author":"EJ Murphy","year":"2022","unstructured":"Murphy, E. J. et al. Immunomodulatory activity of beta-glucan polysaccharides isolated from different species of mushroom - A potential treatment for inflammatory lung conditions. Sci. Total Environ. 809, 152177 (2022).","journal-title":"Sci. Total Environ."},{"key":"2127_CR463","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jconrel.2022.03.028","volume":"346","author":"S Arber Raviv","year":"2022","unstructured":"Arber Raviv, S. et al. Lung targeted liposomes for treating ARDS. J. Control Rel. 346, 421\u2013433 (2022).","journal-title":"J. Control Rel."},{"key":"2127_CR464","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/pharmaceutics13091347","volume":"13","author":"S Kotta","year":"2021","unstructured":"Kotta, S. et al. Lung targeted lipopolymeric microspheres of Dexamethasone for the treatment of ARDS. Pharmaceutics 13, 1347 (2021).","journal-title":"Pharmaceutics"},{"key":"2127_CR465","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.actbio.2022.06.024","volume":"148","author":"W Muhammad","year":"2022","unstructured":"Muhammad, W. et al. ROS-responsive polymer nanoparticles with enhanced loading of dexamethasone effectively modulate the lung injury microenvironment. Acta Biomater. 148, 258\u2013270 (2022).","journal-title":"Acta Biomater."},{"key":"2127_CR466","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jconrel.2021.06.033","volume":"336","author":"PM Mertes","year":"2021","unstructured":"Mertes, P. M. et al. Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation. J. Control Release 336, 252\u2013261 (2021).","journal-title":"J. Control Release"},{"key":"2127_CR467","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.actbio.2018.12.046","volume":"85","author":"W Gao","year":"2019","unstructured":"Gao, W. et al. Size-dependent anti-inflammatory activity of a peptide-gold nanoparticle hybrid in vitro and in a mouse model of acute lung injury. Acta Biomater. 85, 203\u2013217 (2019).","journal-title":"Acta Biomater."},{"key":"2127_CR468","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/CCM.0b013e3181d451ec","volume":"38","author":"JM Constantin","year":"2010","unstructured":"Constantin, J. M. et al. Lung morphology predicts response to recruitment maneuver in patients with acute respiratory distress syndrome. Crit. Care Med. 38, 1108\u20131117 (2010).","journal-title":"Crit. Care Med."},{"key":"2127_CR469","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.chest.2016.03.016","volume":"150","author":"S Mrozek","year":"2016","unstructured":"Mrozek, S. et al. Elevated Plasma Levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: A prospective multicenter study. Chest 150, 998\u20131007 (2016).","journal-title":"Chest"},{"key":"2127_CR470","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03578-6","volume":"25","author":"PD Wendel Garcia","year":"2021","unstructured":"Wendel Garcia, P. D. et al. Latent class analysis to predict intensive care outcomes in Acute Respiratory Distress Syndrome: a proposal of two pulmonary phenotypes. Crit. Care 25, 154 (2021).","journal-title":"Crit. Care"},{"key":"2127_CR471","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03335-1","volume":"24","author":"G Scaramuzzo","year":"2020","unstructured":"Scaramuzzo, G. et al. Gravitational distribution of regional opening and closing pressures, hysteresis and atelectrauma in ARDS evaluated by electrical impedance tomography. Crit. Care 24, 622 (2020).","journal-title":"Crit. Care"},{"key":"2127_CR472","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","volume":"195","author":"KR Famous","year":"2017","unstructured":"Famous, K. R. et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am. J. Respir. Crit. Care Med. 195, 331\u2013338 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2127_CR473","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00134-018-5378-3","volume":"44","author":"P Sinha","year":"2018","unstructured":"Sinha, P. et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 44, 1859\u20131869 (2018).","journal-title":"Intensive Care Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02127-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:01:58Z","timestamp":1741287718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02127-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":473,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02127-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests. Yu Cao is the editorial board member of Signal Transduction and Targeted Therapy, but she has not been involved in the process of manuscript handling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}